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ABSTRACT 
Novel active pharmaceutical ingredients are often poorly water-soluble. Such 
compounds may only partially dissolve or may precipitate during intestinal passage, 
potentially leading to incomplete drug absorption. Despite the importance of the 
process, the underlying in vivo as well as in vitro drug-precipitation mechanisms 
remain poorly understood. Several formulation principles, including lipid-based 
formulations, have been introduced to prevent drug precipitation in the gastro-
intestinal tract. However, in vitro performance testing of these formulations is a topic 
of ongoing scientific discussions. Reliable in vitro tests as well as suitable monitoring 
tools to better analyze in vitro solubilization, precipitation, as well as lipolysis 
processes in the gastro-intestinal tract are required.  
 
In the present thesis, dispersion, dissolution, precipitation, and lipolysis processes are 
discussed. We compared the results obtained with a paddle apparatus with those from 
a physiologically motivated flow-through cell taking lipolysis into consideration, 
using lipid-based formulations of a weakly acidic drug (Biopharmaceutics 
Classification System Class II). We tested pure indomethacin and the drug-containing 
self-microemulsifying drug delivery system (SMEDDS) using pure aqueous buffers 
and biorelevant media. The results of these dispersion/precipitation tests showed 
generally increased solubility of indomethacin in the SMEDDS compared with the 
solubility of the pure drug. One of the SMEDDS was superior compared to the others 
regarding the solubilizing capacity. This was demonstrated only in the flow-through 
test and dispersion in hydrochloric acid (0.1 N HCl). However, these results must be 
interpreted in the light of the lipolysis test showing that the observed differences in 
solubilization were not based on lipolysis. We concluded that suitable characterization 
ABSTRACT ii 
 
 
of SMEDDS involving an acidic drug should include a physiologically motivated 
flow-through test or dispersion/precipitation test in acidic environment, together with 
a lipolysis test. 
 
We studied the effects of polysorbate 80 (PS80) on fenofibrate precipitation in the 
simulated intestinal medium using focused beam reflectance measurement (FBRM). 
We dissolved three different quantities of fenofibrate in six different mixtures of PS80 
and ethanol (EtOH). After adding these formulations to biorelevant media, we 
evaluated the effects of micelles in the simulated medium in combination with PS80 
on fenofibrate solubility and precipitation. Endogenous micelles in combination with 
PS80 micelles enhanced drug solubility and therefore reduced supersaturation. 
Compared to pure water, micelles of biorelevant media accelerated drug-precipitation 
kinetics. Addition of increasing amounts of PS80 to the biorelevant media prolonged 
nucleation time slightly and reduced the number of particles. We successfully 
introduced FBRM as a monitoring tool in biorelevant media. 
 
In another drug precipitation test, we simulated the transfer from the stomach to the 
intestine using simulated gastric and intestinal media. We used online dynamic image 
analysis and inline Raman spectroscopy. Further, we analyzed concentration profiles 
of the model drug dipyridamole in the simulated intestine by high-performance liquid 
chromatography (HPLC), and we developed a kinetic nucleation and growth model 
that was fitted to the experimental data. Dynamic image analysis revealed a complex 
structure of the precipitated dipyridamole particles. These precipitated upon transfer 
to the intestinal medium and were described as star-like crystals or aggregates of 
elongated primary particles. Furthermore, Raman spectroscopy allowed the 
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monitoring of precipitation over time. By fitting the model to the data, nucleation and 
growth exponents were obtained. These were consistent with data published in the 
literature and provided perfect agreement between the model and data.  
 
The last part of the work described in this thesis focused on in vitro lipolysis of lipid-
based drug delivery systems. Dispersion and digestion processes mainly govern the 
fate of such systems. We studied concentration effects of six poorly water-soluble 
drugs on in vitro lipolysis rate of medium-chain triglycerides (MCT), and we 
compared the results with drug effects on oil viscosity and surface tension. First, we 
characterized the drugs by molecular modeling and determined an apparent in vitro 
lipolysis rate in biorelevant medium by potentiometric titration. 
The different drugs exhibited varying effects on oil viscosity and surface tension. 
However, all drugs significantly lowered the apparent lipolysis rate of the oil. This 
effect was very similar among the different compounds and did not correlate with the 
effects on oil viscosity and surface tension. Orlistat was the exception in that it 
practically blocked lipolysis by direct inhibition. The other drugs affected lipolysis 
kinetics most likely by different mechanism(s). In the light of the obtained results, 
drug effect on oil viscosity or surface tension appeared to play a minor role in 
reducing lipolysis rate. The lipolysis kinetics were not affected by the drug load, 
which was deemed advantageous from a pharmaceutical viewpoint. Different dose 
strengths are therefore not assumed to alter lipolysis kinetics, which is beneficial for 
limiting the variability of in vivo drug release.  
 
Moreover, we studied the digestibility of 10 excipients often used in lipid-based drug 
delivery systems. We introduced a mathematical model to describe in vitro lipolysis 
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kinetics, and we defined the relative half-lipolysis time that was independent of the 
set-up of the lipolysis test using Miglyol®812 as the reference excipient. The results 
indicated two classes of excipients. Some additives were partially hydrolyzed, while 
others displayed complete lipolysis. For the latter class, we used the lipolysis extent X 
as a function of time in a simplified mathematical model that provided a good first 
approximation of initial lipolysis kinetics. The relative half-lipolysis time was 
obtained from the model with Miglyol®812 as the reference and seemed to be a 
promising tool for comparing results of in vitro tests employing different 
experimental conditions. 
 
In conclusion, the analytical tools and mathematical models provided new insights 
into in vitro solubilization, precipitation, as well as lipolysis in the gastro-intestinal 
tract. A more complete understanding already at an early stage of drug development 
allows the formation of new, much more efficient lipid-based drug delivery systems 
that minimize drug precipitation.  
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1 INTRODUCTION AND OBJECTIVES 
1.1 Introduction 
Poor water solubility is a main reason for low bioavailability of new active 
pharmaceutical ingredients after oral intake. Poor solubility in gastro-intestinal fluids 
leads to slow and incomplete dissolution of drugs from solid dosage forms. For 
solubilized drugs, this can result in precipitation that leads to limited drug absorption 
with high inter- as well as intrasubject variabilities. Several formulation approaches to 
enhance drug solubility under physiological conditions have been described 
(Brewster, 2008; Kohri et al., 1999; Loftsson and Brewster, 2010; Rabinow, 2004; 
Veiga, 1998). One of them is the lipid-based drug delivery systems (Pouton, 1985). 
Bioavailability of poorly water-soluble drugs may be improved by dissolving them in 
lipid systems, including colloidal dispersions, lipid emulsions, and self-emulsifying 
drug delivery systems (SEDDS). However, the fate of a drug or formulation principle 
in the gastro-intestinal tract depends on various factors. The presence of food or 
excipients, changes in gastro-intestinal motility, as well as pH in the gastro-intestinal 
tract can affect drug solubilization in different ways, depending on the 
physicochemical properties of the active pharmaceutical ingredient. Improved 
understanding of such influences on drug solubilization is important for formulation 
development. 
 
In vitro tests to evaluate drug and formulation behavior under simulated physiological 
conditions are essential for efficient drug development. Although a number of in vitro 
tests to predict the fate of a drug and formulation in the gastro-intestinal tract exist, 
some tests only mimic the environment in the stomach or in the intestine, while others 
simulate the whole gastro-intestinal passage including transfer from the acidic 
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conditions in the stomach into the more neutral conditions in the intestine (Gu et 
al., 2004; Kobayashi et al., 2001; Kostewicz et al., 2004; Vatier et al., 1998). 
However, the performance of drugs trapped in lipid-based delivery systems does not 
only depend on dispersion and/or dissolution. Additionally, digestion of the 
formulation components can significantly influence drug solubility. Therefore, 
lipolysis tests simulating digestion in the intestine were introduced (Fernandez et 
al., 2009; MacGregor et al., 1997; Reymond and Sucker, 1987; Zangenberg et 
al., 2001). Existing results revealed the high complexity of lipolysis processes. 
 
In early work, in vitro tests were usually performed in simple buffer solutions. To 
increase the predictability of in vitro tests, biorelevant media for mimicking 
physiological conditions were introduced. More than 10 years ago, Galia et al. 
proposed fasted state as well as fed state media simulating the stomach and gut (Galia 
et al., 1998). More recently, Jantratid introduced improved media that allow a more 
realistic simulation of drug solubilization in the gastro-intestinal tract, since they 
contain substances of physiological relevance such as bile salts and phospholipids 
(Jantratid et al., 2008). 
 
Despite the considerable efforts applied to biopharmaceutical research, the processes 
following oral administration of lipid-based formulations remain insufficiently 
understood. Once the formulation is in contact with the aqueous medium of the 
gastro-intestinal tract, complex processes are initiated. These are strongly influenced 
by the physiological conditions in the gastro-intestinal tract as well as the formulation 
properties. 
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1.2 Objectives 
The goal of this PhD research was to gain new insight into the behavior of poorly 
water-soluble drugs in the gastro-intestinal tract using lipid-based formulations. This 
included the following parts: 
 
1) Study of dispersion, dissolution, precipitation, and lipolysis of these drug 
formulations. 
2)  Implementation of novel analytical tools to monitor drug precipitation with 
respect to particle number and size and shape of the precipitates/aggregates. 
3)  Comparison of different in vitro tests used to evaluate drug formulations. 
4) Where appropriate, establishment of theoretical models to describe the relevant 
processes. 
 
As model compounds we selected poorly water-soluble drugs, including weak acids, 
weak bases, and neutral substances. The formulations consisted of pure oil, pure 
excipients, or SEDDS, including mixtures of oils, surfactants, and cosurfactants. We 
performed the experiments in acidic solutions or phosphate buffer, and in biorelevant 
media simulating the physiological conditions.  
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2 THEORETICAL SECTION 
2.1 Biopharmaceutics Classification System 
Modern techniques, such as high-throughput screening or combinatorial chemistry, 
facilitate the speedy identification of new, highly potent chemical entities. Very often 
new compounds exhibit higher molecular weights and lower water solubility 
compared to drugs already on the market (O’Driscoll, 2008). Substances in 
development are categorized by means of the Biopharmaceutics Classification System 
(BCS), introduced by Amidon et al. in 1995. This system is a valuable tool and forms 
part of the regulatory guidance issued by the American Food and Drug 
Administration (FDA) as well as World Health Organization (WHO) (Dahan et 
al., 2009). The system categorizes drugs into four classes depending on their 
solubility and permeability (Figure 2-1). Class I drugs exhibit high solubility and high 
permeability, Class II drugs show low solubility and high permeability, Class III 
substances demonstrate high solubility and low permeability, and finally, in case of 
Class IV drugs, both characteristics are low. 
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Figure 2-1: Biopharmaceutics Classification System (Pouton, 2006) 
The BCS II substances present the greatest challenge in the field of pharmaceutical 
technology. If membrane permeability is good, the rate-limiting step is solubility that 
can be altered by formulation principles. As indicated in Figure 2-1, it would be 
possible to convert a BCS II drug into a BCS I drug, using a suitable formulation. 
Since only the dissolved fraction of drug is available for absorption, it is of prime 
importance to keep the drug in a solubilized state during the whole gastro-intestinal 
passage. Otherwise, the drug would exhibit poor and variable bioavailability.  
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2.2 Drug solubility in the gastro-intestinal tract 
The FDA recommendations stipulate that drug solubility is determined by dissolving 
the highest unit dose of the compound in 250 ml buffer in the range between pH 1.0 
and 8.0. A drug is considered highly soluble if the solubility volume is less than, or 
equal to, 250 ml. Solubility of a compound in the gastro-intestinal tract depends on 
various factors that change along the tract. The physicochemical parameters of the 
active pharmaceutical ingredient primarily define solubility. Substance properties 
such as pKa, diffusivity, lipophilicity, surface area, hydrogen bonding, particle size, as 
well as crystal form can influence the solubilization behavior. 
Moreover, the environment in the gastro-intestinal tract significantly affects 
solubility. Physiological as well as pathological processes can influence the 
environment in the stomach and intestine. Under physiological conditions in the 
fasted state, drugs undergo a marked pH change during gastro-intestinal passage. 
After the acidic conditions (pH 1.5-2) in the stomach, drugs are exposed to a more 
neutral environment (pH 4.9-6.4) in the intestine (Fleisher et al., 1999). This change is 
relevant for drug delivery, since many compounds are weak acids or weak bases. In 
such cases, pH affects ionization and therefore also the solubilization behavior of 
drugs. As an example, the weak base dipyridamole, pKa = 6.4 (www.roempp.ch), is 
readily soluble in the acidic environment of the stomach. In the upper intestine, the 
pH is higher so that drug solubility decreases due to deprotonation. As a consequence, 
the base will precipitate. The opposite situation occurs with poorly water-soluble 
acids. They exhibit low solubility in the stomach and higher solubility in the gut. 
Under fed conditions, the pH characteristics are different. In the early days, food in 
the gastro-intestinal tract was regarded as a barrier to absorption. It was recommended 
to take drugs on an empty stomach (Wagner, 1977; Welling, 1977). These days, it is 
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generally accepted that food typically influences the solubility of a drug and therefore 
can impact on oral bioavailability (Fleisher et al., 1999). Depending on the type of 
meal, the pH in the stomach increases and therefore precipitation of drugs in the 
stomach is different in the fed than the fasted state. In addition, gastric emptying 
varies, since the emptying rate is associated with the pH, volume of the content, 
calories, viscosity, and osmolarity (Fleisher et al., 1999; Shafer et al., 1985). As an 
example, the rate of gastric emptying decreases if the gastric pH increases and the 
other way round if gastric pH decreases. Under fed conditions, secretion of 
endogenous solubilizing components in the small intestine is enhanced. As reported 
by Persson et al., total bile salt concentration in the jejunum is 2 ± 0.2 mM in the 
fasted state but is as high as approx. 8 ± 0.1 mM in the fed state (Persson et al., 2005). 
These authors also reported that phospholipid concentrations increase by a factor of 
15, from 0.2 mM under fasted conditions to 3 mM under fed conditions (Persson et 
al., 2005). Thus, the increased concentration of colloidal substance improves the 
solubility of poorly soluble drugs. Bakatselou et al. showed that the higher 
concentration of bile salts under fed conditions improves the solubility of steroids 
(Bakatselou et al., 1991). Moreover, concomitant intake of food increases the 
bioavailability of fenofibrate (which is approx. 30% when taken without food) by 
approximately 35% to 65% (Guay, 1999). Another factor affecting the solubility of 
drugs is the age of treated subjects. Studies have shown that 10% of individuals over 
65 years of age have a gastric pH greater than pH 6 in the fasted state (Russell et 
al., 1994).  
Apart from physiological factors, disease states may affect the solubilizing capacity in 
the gastro-intestinal tract. For example, subjects suffering from human 
immunodeficiency virus (HIV) tend to have a higher gastric pH, and cystic fibrosis 
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patients have a lower gastric pH (Herzlich et al., 1992; Youngberg et al., 1987). 
Furthermore, gastric pH can be influenced by concomitant treatment with other drugs. 
Blum et al. for example showed that an increase of the pH due to antacids lowers the 
bioavailability of the antifungal drugs fluconazole and ketoconazole (Blum et 
al., 1991). 
In view of the complexity of the physiological conditions, it remains a challenge to 
keep the drug in a dissolved state during the entire gastro-intestinal passage, 
particularly since the conditions in the two parts of the gastro-intestinal tract are 
completely different. Therefore, development of efficient formulation principles that 
avoid drug precipitation requires a better understanding of drug precipitation 
processes. The following chapter gives an introduction into precipitation processes. 
2.3 Precipitation 
Poorly water-soluble drugs may precipitate in the gastro-intestinal tract. Precipitation 
is a complex process based on three steps. In a first, essential step, supersaturation has 
to be reached. This means that the concentration of the solubilized drug is above the 
saturation solubility. Equation 2.1 expresses the degree of supersaturation: 
  
SS = S
Seq
                                                                                                                    (2.1)
 
 
where S represents the actual concentration and Seq is the equilibrium solubility. In a 
supersaturated system, the drug solution is thermodynamically unstable and will 
return to the equilibrium state by drug precipitation. Ostwald introduced the terms 
“metastable” and “labile” supersaturation (Ostwald, 1897). In case of metastable 
supersaturation, precipitation does not occur spontaneously, but in the presence of 
crystal seeds, nucleation and particle growth appear. In the labile zone, precipitation 
occurs in every case. 
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After supersaturation is reached, the process continues with nucleation. As shown in 
Figure 2-2, different types of nucleation exist. If a system does not contain any 
crystals, the process is named primary nucleation. Primary nucleation is subdivided 
into homogeneous and heterogeneous nucleation, depending if nucleation occurs 
spontaneously or if it is induced by foreign particles. In case of nucleation induction 
by crystals, the process is referred to as secondary nucleation. 
 
Figure 2-2: Nucleation nomenclature (adapted from Mullin, 2001) 
Today, different models exist for describing nucleation processes (Erdemir et 
al., 2008; Vekilov, 2010). The most widely used theory is the Classical Nucleation 
Theory (CNT) developed by Gibbs (Gibbs, 1948). In this thermodynamic approach 
(see Figure 2-3), ∆G is the driving force of the nucleation processes. On the one side, 
there is the free energy change for the phase transformation ∆Gv, which favors particle 
growth, and on the other side there is the free energy change for the surface formation 
∆Gs, which prefers particle dissolution. With small particles, ∆Gs causes an increase 
in total free energy. After reaching an energy maximum at the critical size rc, total 
free energy decreases and nucleus formation can start. With heterogeneous 
nucleation, the free energy maximum at the critical size of the radius is lower than 
that with homogeneous nucleation. 
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Figure 2-3: Free energy diagram for nucleation (Vekilov, 2010) 
In case of homogeneous primary nucleation, the formation of stable nuclei is based on 
assumptions. It probably results from a sequence of bimolecular additions of 
molecules until the critical size is reached. Further addition of molecules leads to 
nucleation and particle growth (Mullin, 2001). The number of molecules in a stable 
nucleus varies from ten to several thousands. However, formation of critical nuclei is 
a dynamic process. As explained above, several steps are required before the critical 
size is reached and nucleation processes as well as particle growth can continue. The 
many subnuclei formed are labile and therefore redissolve rapidly.  
In reality, homogeneous nucleation occurs rarely. Most nucleation processes are 
based on heterogeneous nucleation, since it is rather difficult to eliminate all foreign 
particles in a solution (Mullin, 2001). 
Because lipid-based formulations were of primary interest in this PhD research, I 
discuss this formulation principle in detail below. 
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2.4 Lipid-based drug delivery systems 
Based on the positive effects of food on bioavailability, lipid-based drug delivery 
systems were introduced in which the drug is solubilized (Hong et al., 2006; Porter et 
al., 2008). Thus, solid-liquid phase transition is avoided (Charman et al., 1992). Lipid-
based drug delivery systems include lipid suspensions, lipid emulsions, or SEDDS. 
The latter is of special interest in this work. In 1985, Pouton established SEDDS 
(Pouton, 1985). At this time, solid-phase formulations were much more important 
than SEDDS but the successful marketing of the first lipid system changed this 
situation. Sandimmun (cyclosporine A) proved the suitability of lipid-based drug 
delivery systems. Today, several lipid-based formulations are commercially available 
(Strickley, 2004; Strickley, 2007). 
Lipid-based systems range from simple oils to complex mixtures (Pouton, 2006). In 
2000, Pouton introduced the Lipid Formulation Classification System (LFCS), which 
takes the composition of the formulations as well as the fate of formulations in the 
gastro-intestinal tract into account (Pouton, 2000).  Table 2-1 shows the classification 
system encompassing five types of formulations and their characteristics. 
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Excipients Content of formulation (%, w/w) 
 Type I Type II Type IIIA Type IIIB Type IV 
 
Oils 
 
100 40-80 40-80 < 20 - 
 
Water-
insoluble 
surfactants 
(HLB < 12) 
 
- 20-60 - - 0-20 
 
Water-soluble 
surfactants 
(HLB > 12) 
 
- - 20-40 20-50 30-80 
 
Hydrophilic 
cosolvents 
 
- - 0-40 20-50 0-50 
HLB: hydrophilic-lipophilic balance 
 Table 2-1: Lipid Classification System (Pouton, 2006) 
The hydrophilic fraction increases from type I to type IV. Type I formulations contain 
only oil and require digestion to free fatty acid and 2-monoglycerides. These 
degradation products build colloidal dispersions within bile salt-lecithin mixed 
micelles. Due to its simplicity, type I formulations are the type of choice for drugs 
with a log P > 4. Addition of lipophilic surfactants (Hydrophilic-Lipophilic Balance 
[HLB] < 12) to oils leads to type II formulations. Since they emulsify in aqueous 
solutions under gentle agitation, they are named “self-emulsifying drug delivery 
systems” (SEDDS). They are thermodynamically stable if there is a relatively small 
volume of the dispersed oil phase and a narrow range of droplet size distribution 
(Shah et al., 1994). The amount of surfactant should be in the range of 20% to 60% 
(w/w). Starting from a surfactant concentration of 25%, self-emulsification occurs. At 
concentrations around 65%, depending on the surfactant, the self-emulsifying process 
is slowed by a viscous liquid crystalline gel, formed at the oil-water interface. Such a 
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system is able to build a stable emulsion, but for emulsifying processes, energy is 
needed. Type III formulations contain hydrophilic surfactants (HLB > 12) and/or 
cosolvents such as EtOH, propylene glycol, or polyethylene glycol. They form very 
fine particles and are therefore named “self-microemulsifying drug delivery systems” 
(SMEDDS). Such microemulsion preconcentrates are of substantial interest to the 
pharmaceutical industry as well as academic research. Some recent articles reported 
the use of SMEDDS to formulate itraconazole (Woo et al., 2007), fenofibrate (Mohsin 
et al., 2008), vinpocetine (Chen et al., 2008), and oridonin (Zhang et al., 2008). Since 
the hydrophilic fraction can influence precipitation, type III formulations are 
subdivided into type IIIA and type IIIB formulations. The latter contains higher 
amounts of hydrophilic substances that enhance the risk of drug precipitation (Pouton, 
2000).  
In 2006, Pouton introduced an additional type IV formulation that solely contains 
hydrophilic surfactants and cosolvents (Pouton, 2006). Type IV formulations are used 
for drugs that are hydrophilic but not lipophilic. A disadvantage of these formulations 
is the tendency of high local surfactant concentrations that may cause irritations 
(Attwood and Florence, 1983). Therefore, if this formulation is used on a regular 
basis, it might not be well tolerated. 
2.4.1 Oils 
In lipid-based oral formulations, medium-chain triglycerides (e.g. coconut oil, palm 
seed oil, Miglyol) or long-chain triglycerides (LCT) (e.g. peanut oil, sesame oil, olive 
oil) are commonly used. Triglycerides enhance drug solubility in the gastro-intestinal 
tract. On the one hand, they stimulate secretion of bile salts and phospholipids. On the 
other hand, the degradation products after digestion form mixed micelles together 
with the endogenous bile salts and phospholipids (Hernell et al., 1990). To promote 
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drug solubilization, mixed glycerides are often incorporated into formulations (Pouton 
and Porter, 2008). 
Efforts were made to test the solubilizing potential of the medium as well as long- 
chain triglycerides. It was shown that digestion of oils depends on the length of fatty 
acids (Porter at al., 2004; Sek et al., 2002). Digestion of a medium-chain triglyceride 
to a 2-monoglyceride and two fatty acids is faster than digestion of a long-chain 
triglyceride. This difference is of prime importance for a drug dissolved in oil. If 
digestion of triglycerides is slow, a poorly water-soluble drug can stay in the 
undigested oil for a longer time period. In case of faster digestion, the drug can be 
dispersed into the aqueous phase, or precipitation can occur.  
Recently, a novel class of excipients for lipid-based drug delivery systems was tested 
(Holm et al., 2011). They compared an indigestible semi-fluorinated alkane, 1-
perfluorohexyloctane, with a long-chain triglyceride and a medium-chain triglyceride. 
Since the results showed no clear benefits, the usefulness of semi-fluorinated alkanes 
as inherent part of lipid-based drug delivery systems is still uncertain. 
2.4.2 Surfactants 
Further components of lipid-based drug delivery systems are surfactants. They are 
amphiphilic molecules consisting of a polar head and a nonpolar tail, composed of 
saturated or unsaturated fatty acids. Depending on the properties of the head group, 
anionic, cationionic, amphoteric, or nonionic surfactants exist. At low concentrations, 
surfactants adsorb on surfaces or interfaces, reducing surface or interface tension. As 
shown in Figure 2-4, micelles are formed above the critical micelle concentration 
(CMC) of the surfactant. 
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Figure 2-4 : Micelle formation (Rangel-Yagui et al., 2005) 
The hydrophilic heads build the surface of the micelles, whereas the hydrophobic tails 
accumulate in the core of the micelle. Formation of micelles is based on 
intermolecular forces such as hydrogen bonds, van der Waals forces as well as 
hydrophobic, steric, and electrostatic forces. In addition, HLB values of the 
surfactants play an important role. Previous studies showed that the most efficient 
surfactants considering micelle formation are those with HLB values ranging 
from 12 to 15 (Thi et al., 2009). Regarding the inner, hydrophobic part of micelles, 
we can distinguish between two regions: one outer phase still containing water and an 
inner phase completely free of water. This is important for the solubilization capacity 
of micelles, i.e. the main advantage of this system. 
 
Figure 2-5: Possible locations of drugs in micelles (Rangel-Yagui et al., 2005) 
Figure 2-5 shows different locations of drugs (I) in the micelles, depending on the 
drug properties. A nonpolar drug accumulates in the core of the micelle. Drugs with 
intermediate hydrophilicity/hydrophobicity accumulate in an intermediate position in 
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the micelle (Torchilin, 2001). In general, the position of the drug moves in the 
direction of the surface of the micelle with increasing polarity of the drug. 
Nonionic surfactants are excellent solubilizing agents. They exhibit lower CMC 
values than the other surfactants. This is of main importance with respect to the 
physiological conditions in the gastro-intestinal tract. Micelles undergo marked 
dilution first in the stomach and afterwards in the intestine. It is known that only those 
micelles that consist of surfactants with low CMC values still exist after dilution in 
large volumes (Yokoyama, 1992). Micelles composed of surfactants with high CMC 
values dissociate after dilution, and the probability of drug precipitation increases 
immediately. In addition, nonionic surfactants show a good safety profile because 
they cause less mucosal irritation in the gastro-intestinal tract. However, nonionic 
surfactants can cause reversible changes in intestinal mucosal permeability leading to 
facilitated absorption of the co-administrated drug (Gursoy and Benita, 2004). 
2.4.3 Cosolvents 
Cosolvents, e.g. EtOH, glycerol, polyethylene glycol, propylene glycol, or transcutol 
are used to facilitate dispersion of the surfactants and to increase solvent capacity 
(Pouton, 2006). For the latter purpose, high concentrations of cosolvents are needed. 
This increases the risk of precipitation, since cosolvents lose their solvent capacity in 
case of dilution in the gastro-intestinal tract (Pouton and Porter, 2008). Moreover, 
cosolvent concentrations have to be chosen carefully due to potential incompatibility 
with capsule shells (Cole et al., 2008). 
 
A plethora of different lipid-based formulations can be constructed, and, depending 
on the drug, the behavior of each formulation may be different. Chambin et al. 
demonstrated that the polarity of a drug influences wettability, thermal behavior, 
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microscopic aspects, as well as the release properties of the lipid-based formulation 
(Chambin et al., 2009). However, in vitro tests for an early assessment of the fate of 
the formulation in the gastro-intestinal tract are of prime importance. 
2.5 In vitro tests 
In vitro tests for reliable prediction of the solubilization behavior of a 
drug/formulation under physiological conditions are indispensible. Such tests should 
predict the fate of a drug in the gastro-intestinal tract already at an early stage of 
development. Experiments in animals as well as humans could be minimized, thus 
lowering the costs and saving time. The following chapter gives an overview of the 
established in vitro tests. 
2.5.1 Biorelevant media 
The purpose of an in vitro test is to mimic physiological conditions as close to reality 
as possible. For dissolution testing, experiments are usually performed in water, 
aqueous hydrochloric acid, or aqueous buffer solutions (pH 4.4-8.0). However, these 
aqueous buffer solutions do not simulate physiological conditions. Efforts were made 
to develop test media simulating physiological conditions. At the beginning, media 
contained artificial surfactants without physiological relevance or they included 
physiological substances at concentrations different from the physiological 
concentrations (Dressman et al., 1998). Typically used media are Simulated Gastric 
Fluid (SGF) and Simulated Intestinal Fluid (SIF) (United States Pharmacopeia 
[USP], 2011). SGF is a hydrochloric acid solution, pH 1.2, containing large amounts 
of pepsin which differs from physiological conditions. Since pepsin is a protease, it is 
of minor importance for studying the fate of lipid-based drug delivery systems. SIF is 
a phosphate buffer, pH 6.8, containing large amounts of pancreatin, which is 
important for the digestion of lipid-based drug delivery systems. However, the 
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usefulness of pancreatin concentrations much higher than those encountered 
physiologically under fasted conditions is questionable. In 1998, Galia et al. 
introduced two media, simulating conditions in the proximal small intestine in the 
fasted as well as fed state (Galia et al., 1998). These media were used extensively in 
industrial and academic work. It was demonstrated that experiments performed in 
biorelevant media are suitable for in vitro/in vivo correlations (Dressman and 
Reppas, 2000; Nicolaides et al., 1999). The composition of these media was later 
modified to reduce costs and preparation time. In addition to the existing intestinal 
media, Vertzoni et al. created Fasted Stated Simulated Gastric Fluid (FaSSGF) for a 
better simulation of the physiological conditions than the gastric fluids of the USP 
(Vertzoni et al., 2005). As the comparison with human gastro-intestinal contents 
showed, there was still a need for improvement (Kalantzi et al., 2006). In 2008, 
Jantratid et al. introduced modified biorelevant media which were claimed to be of 
higher physiological relevance and better stability than the previous versions. 
Jantratid et al. developed an adjusted Fasted State Simulated Intestinal Fluid 
(FaSSIF V2) and “snapshot” media for simulating the fed state in the gastro-intestinal 
tract. “Early”, “middle”, and “late” Fed State Simulated Gastric Fluid (FeSSGF) as 
well as Fed State Simulated Intestinal Fluid (FeSSIF) simulate variable time points 
after meal intake. Although the biorelevant media are well adjusted to physiological 
conditions, discussions about the optimal composition are still ongoing und further 
adaptions are expected. 
2.5.2 In vitro testing of oral dosage forms 
2.5.2.1 USP dissolution equipments 
In 1950, the USP introduced disintegration tests. Since it was recognized that only 
dissolved drug is available for absorption, it became clear that disintegration tests are 
19  THEORETICAL SECTION 
 
 
not suited for reliable prediction of in vivo/in vitro correlations. As a consequence, 
dissolution testing started in 1968, and the USP I apparatus was introduced (Cohen et 
al., 1990).  
This was the onset of the development of various UPS apparatus. USP I and USP II 
apparatus are the most widely used equipments for testing the performance of oral 
drug delivery systems. Test media are placed in a standardized beaker under constant 
temperature and adjustable stirring rates. The only difference between USP I and 
USP II is the stirring device. Using USP I apparatus, capsules or tablets for testing are 
placed in a rotating basket. In contrast, in the USP II apparatus, the drug is placed in 
the reaction vessel and if the dosage form floats, it can be weighted with a sinker. A 
paddle is used as a stirrer. A suitable pH as well as an appropriate stirring speed has to 
be selected in both devices. 
The USP I and USP II apparatus allow dissolution testing in one single reaction 
medium at defined pH. From a physiological point of view, the volumes of these 
dissolution tests are too large. Schiller et al. showed that the volumes in the stomach 
and small intestine are much lower (Schiller et al., 2005). Under fasted conditions, the 
volumes are in the range of 13 ml to 72 ml in the stomach and 45 ml to 319 ml in the 
small intestine. The volume in the stomach under fed conditions is much larger 
(534 ml to 859 ml). The volume in the small intestine is in the range of 20 ml to 
156 ml. 
The improved USP III apparatus was introduced in 1991. The reciprocating glass 
cylinders allow the simulation of a process in a moving medium. The hydrodynamics 
of the USP III are more favorable than those of the USP I and II (Jantratid et 
al., 2008). In addition, the USP III enables an easy change of the reaction medium for 
a better simulation of the physiological conditions. In the USP IV, employing the 
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flow-through method, the sample is placed in a flow-through cell, where the media 
can pass at different flow rates and where sink conditions are maintained. In an 
“open-loop” configuration, the cell is floated with fresh medium, and the volumes can 
be infinite. Using a “closed loop”, the amount of medium is fixed and is recirculated 
through the flow-through cell. The volume of the medium can vary from a few 
milliliters to several liters if necessary. The advantages of the flow-through method 
over the methods utilized by USP I/II are different hydrodynamics and mixing effects. 
Contrary to the USP I and USP II, coning or dead zones are eliminated. 
However, these compendial dissolution tests are limited in the predictability of 
physiological conditions. Therefore, additional tests were introduced by other groups 
and by us to improve the imitation potential. 
2.5.2.2 Biopharmaceutical transfer tests 
To improve predictability, drug transfer tests were introduced. An example of such a 
test is the artificial stomach duodenal model (ASD) (Vatier et al., 1990; Vatier et 
al., 1998). Drug is first dispersed in the “stomach chamber” and afterwards transferred 
into the “duodenum chamber”, where the concentration of solubilized drug is 
monitored by ultraviolet visible (UV/Vis) spectroscopy. The model was successfully 
used in dog studies in both the fasted and fed states (Carino et al., 2006). However, 
caution is warranted if drug bioavailability is influenced by permeability and 
metabolism. In 2001, Kostewicz et al. came up with a biopharmaceutical test in which 
the drug is first dissolved in the simulated stomach medium and then transferred to 
the more neutral simulated upper intestine (Kostewicz et al., 2001). For simulating 
variable gastric emptying states, they used different transfer rates and to mimic 
motility, they varied the stirring rates. Another test was introduced by Kobayashi et 
al., which simulates not only drug transfer from the simulated stomach into the 
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simulated intestine but also the absorption step (Kobayashi et al., 2001). Three years 
later, Gu et al. developed a multicompartment dissolution system containing a 
simulated stomach compartment, an artificial intestinal compartment, and a simulated 
absorption compartment (Gu et al., 2004).  
All these tests are closer to the physiological conditions than the compendial 
dissolution tests. However, in these biopharmaceutical transfer tests, a digestion step 
that is especially important for lipid-based formulations is still missing. Components 
of such formulations can typically be digested and therefore a digestion step should be 
considered in an in vitro test. 
2.5.2.3 Lipolysis tests 
Once a drug enters the upper intestine, digestion of the formulation starts. Lipolysis in 
the intestine is a complex process. Basic aspects of this biochemical process were 
excellently reviewed by Verger and Haas in 1976. They showed that lipases are 
special esterases that do not follow the Michaelis-Menten kinetics due to the 
interfacial catalysis. Lipolysis is influenced by the stereospecificity of the enzyme, the 
quality, and form of the reaction interface (monolayer, bilayer, micelles), the size of 
the substrate droplets, the orientation of the substrate molecules at the interface, the 
chain lengths of the substrates, and the presence of inhibitors that can be 
physiological or artificial substances. 
Several groups have come up with lipolysis tests, simulating digestion processes in 
the intestine (Fernandez et al., 2009; MacGregor et al., 1997; Reymond and 
Sucker, 1987; Sek et al., 2002; Zangenberg et al., 2001). Comparison of the different 
in vitro lipolysis tests shows many experimental differences, such as duration of the 
tests as well as sampling times, for example. However, the most important differences 
comprise the use of media at different pH, varying amounts of formulation added, and 
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different activities of lipases. Another critical point is the addition of Ca2+-ions, both 
with respect to the final concentration and the method of addition. Some groups added 
Ca2+-ions as a bolus at the beginning of the experiments, while others added the ions 
continuously during the experiment. This experimental difference changes the 
reaction conditions significantly (Zangenberg et al., 2001). During digestion, liberated 
free fatty acids accumulate at the interface of the micelles and can sterically hinder 
the attachment of the lipase, resulting in a reduction of the lipolysis rate. Ca2+-ions are 
added to form calcium soaps with the free fatty acids, which then precipitate and thus 
are removed from the surface of the micelles. If the Ca2+-concentration is higher than 
the amount of free fatty acids, they can precipitate fatty acids incorporated in the 
mixed micelles and bile acids. Both reactions lead to a change of the micelle 
composition and consequently to an altered dissolution capacity (Larsen et al., 2008). 
Thus, Ca2+-ions are needed to increase lipase activity (Alvarez and Stella, 1989). 
Fernandez et al. established a new lipolysis test containing a gastric phase (Fernandez 
et al., 2009). This constitutes an eligible reaction step, since it is known that gastric 
lipases hydrolyze approx. 10% to 20% of the triglycerides (Fatouros and 
Muellertz, 2007). Another lipolysis test is in development by the group of Muellertz 
et al. They intend to combine a lipolysis test with drug absorption, using Caco-2 cell 
monolayers (Larsen et al., 2011). 
At present, standard procedures for lipolysis testing do not exist. Comparison of the 
outcomes of different experiments is therefore rather difficult. Even though the 
experimental conditions are still under evaluation, lipolysis tests already demonstrated 
suitability with respect to the in vivo situation. Dahan and Hoffman demonstrated 
excellent correlation between in vitro data and bioavailability data of progesterone 
and vitamin D3 in rats (Dahan and Hoffman, 2006). In another experiment, Fatouros 
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et al. showed that in vitro results from lipolysis tests for probucol in three different 
formulations were in good agreement with in vivo results in fed minipigs (Fatouros et 
al., 2008). 
2.6 Analytical tools: needs and challenges for monitoring 
drug precipitation in biorelevant media 
Appropriate simulation of physiological conditions is one goal in the development of 
novel in vitro tests. In addition, the process of drug dissolution should be better 
understood, and reliable monitoring tools are indispensible. Especially drug 
precipitation in biorelevant media requires suitable analytical tools for close 
monitoring of precipitation. In chemical and pharmaceutical industry, various 
analytical technologies have been introduced, mainly in the context of process 
analytical technology with the aim to monitor manufacturing processes. In contrast, 
analytical tools to investigate biopharmaceutical in vitro processes are rarely used.   
Process analytical tools can be used in different measurement modes such as offline, 
atline, online, inline, or non-invasive (Yu et al., 2004). With offline analytical 
methods, the sample is removed from the reaction mixture and is analyzed in a 
separate place, whereas with atline analysis, the sample is analyzed in a place close to 
the manufacturing site. Offline and atline methods have the disadvantages that the 
samples are analyzed with a time delay and may therefore have been altered. In online 
analytics, the samples are redirected to the analytical tool and immediately returned 
into the reaction mixture after analysis. Inline measurements provide real-time 
analysis by placing the sensor directly into the samples. An obvious disadvantage of 
this mode is that the process may be disturbed by contact with the probe.  
Process analytics are used in several areas, e.g. in crystallization studies of new active 
pharmaceutical ingredients. UV/Vis spectroscopy, infrared spectroscopy, near-
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infrared spectroscopy, Raman spectroscopy, FBRM, endoscopy, or chemical imaging 
techniques are used (Bugay, 2001; Gao et al., 2009; Simon et al., 2009; Stephenson et 
al., 2001). 
It would be beneficial to use such analytical tools for drug precipitation monitoring in 
biorelevant media. As mentioned, monitoring the fate of the drugs under simulated 
physiological conditions is a rather unexplored field. However, the knowledge 
available based on the use of monitoring tools in different fields is advantageous. To 
obtain real-time results and to avoid errors in measurements due to subsequent 
treatments, inline or non-invasive analytical tools are favored. However, some media, 
e.g. Fasted State Simulated Intestinal Fluid (FaSSIF), are turbid, which can be a 
problem in the detection of very small precipitates since the detection is covered by 
the signals of the medium. The possibility of a “blind spot” in the analysis of the 
precipitates must to be borne in mind. Another disadvantage is the fact that 
biorelevant media hamper the detection of different polymorphs in the reaction 
mixture. Therefore, not every method is suitable as an analytical tool for biorelevant 
media. The tool has to be selected very carefully and research is needed to evaluate 
the most suited analytical tools for drug precipitation in biorelevant media.  
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3 COMPARISON OF DIFFERENT IN VITRO TESTS TO 
ASSESS ORAL LIPID-BASED FORMULATIONS 
USING A POORLY SOLUBLE ACIDIC DRUG 
3.1 Introduction 
In the following chapter we compared the behavior of formulations in dissolution tests 
as well as a lipolysis test. Oral lipid-based systems are often assessed using 
compendial dissolution equipment. Since the drug is generally dissolved in the 
formulation, the test primarily characterizes dispersion of the formulation and 
partitioning of the drug into the aqueous medium. In some cases, precipitation may 
occur and the tests can show the extent of drug redissolution. The suitability of the 
existing dissolution tests for lipid-based systems is currently not fully explored and is 
therefore an area of ongoing research. 
Another area of current interest is to study the digestion of lipid-based systems by 
means of an in vitro lipolysis test. As mentioned before different in vitro lipolysis 
models are known (Cuiné et al., 2007; Fernandez et al., 2007; Zangenberg et 
al., 2001), which mainly differ by the way of how the calcium ions are added. 
Harmonization of the test protocols and a better understanding of these in vitro tests 
using lipid-based formulations are crucial for a rational and efficient formulation 
development. 
In the present work, we used three formulations of type 3 of which one was semisolid 
and the others were liquid. These SMEDDS comprised oils, surfactants, cosolvents, as 
well as the model drug indomethacin, a weakly acidic BCS class II compound. 
Employing the USP II apparatus, we used 0.1 N HCl, phosphate buffer pH 6.8, and 
biorelevant media (Vertzoni et al., 2004; Vertzoni et al., 2005). The results were 
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compared with those of a dynamic USP IV method as well as with the outcome of a 
lipolysis test in biorelevant media. 
3.2 Materials and Methods 
3.2.1 Materials 
Indomethacin (pKa indomethacin = 4.5 [Dollery, 1998]), sodium taurocholate, 4-
bromophenylboronic acid, calcium chloride dihydrate, porcine pancreatin, hog pepsin, 
potassium chloride, potassium dihydrogen phosphate, potassium phosphate dibasic 
anhydrous, sodium chloride, 0.2 N hydrochloric acid, and 0.2 N sodium hydroxide 
were purchased from Sigma-Aldrich GmbH, Switzerland. Hydrochloric acid (1 N), 
hydroxide solution (1 N), monobasic potassium phosphate, and sodium hydroxide 
were obtained from Riedel-de Haën AG, Germany. Gelucire®44/14, Labrafil®M-2125 
CS, and Transcutol®HP were supplied from Gattefossé GmbH, France. Ethanol 96 %, 
Imwitor®742, Miglyol812, pepsin, and phosphoric acid 85 % were purchased from 
Hänseler AG, Switzerland. Cremophor®RH 40 and Solutol®HS 15 were obtained 
from BASF AG, Switzerland. Acetonitrile HPLC grade was supplied from 
Mallinckrodt Baker, Inc., United States, and phopsphatidylcholine was obtained from 
Lipoid GmbH, Germany. 
3.2.2 Methods 
3.2.2.1 Aqueous buffer systems and simulated gastro-intestinal fluids 
Equilibrium solubility of indomethacin was determined in different aqueous buffer 
systems and simulated gastro-intestinal fluids. 
The different citrate buffer solutions and phosphate buffer solutions were 
manufactured as described (Geigy, 1973). Phosphate buffer pH 6.8, containing NaCl, 
was prepared according to the European Pharmacopeia (Ph.Eur.), 2008. Table 3-1 
shows the composition of various biorelevant media. 
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 SGF SIF FaSSGF FaSSIF FeSSIF 
NaTC (mM) - - 8*10-2 3 15 
Lecithin (mM) - - 2*10-2 0.75 3.75 
KCl (mM) - - - - 204 
KH2PO4 (mM) - 50 - - - 
Maleic anhydride 
(mM) - - - 25 - 
NaCl (mM) 34 - 34 109 - 
NaOH (mM) - 15.4 - 45 - 
Pancreatin (g) - 10 - - - 
Pepsin (µM) 93 - 1.24 - - 
pH 1.2 6.8 1.6 6.5 5 
SGF: Simulated Gastric Fluid, SIF: Simulated Intestinal Fluid, FaSSGF: Fasted State Simulated Gastric 
Fluid, FaSSIF: Fasted State Simulated Intestinal Fluid, FeSSIF: Fed State Simulated Intestinal Fluid 
Table 3-1: Compositions of biorelevant media 
3.2.2.2 Preparation of pancreatin suspension 
Porcine pancreatin (3478 mg) was suspended in 20 ml FaSSIF. After stirring the 
suspension at room temperature (15 min, 25 ± 0.5°C), the suspension was centrifuged 
with an Eppendorf Centrifuge 5415C (15 min, 14000 rpm) from Vaudaux-
Eppendorf AG, Switzerland. The clear supernatant was collected and pH was adjusted 
using 1 N NaOH. The resulting solution exhibited an enzyme activity of 
10000 tributyrin units (TBU) per ml, whereas 1 TBU is the amount of enzyme that 
liberates 1 µmol of titratable fatty acid from tributyrin per minute. The solution was 
freshly prepared each day. 
3.2.2.3 Preparation of self-microemulsifying drug delivery systems 
Gelucire®44/14, Cremophor®RH 40, and Solutol®HS 15 were melted, and 
Labrafil®M-2125 CS was warmed up to eliminate flocculation. Afterwards, 
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formulations were prepared according to the following compositions: formulation 1 
[Gelucire®44/14: Transcutol®HP: Labrafil®M-2125 CS, 76: 19: 5, w/w], 
formulation 2 [Cremophor®RH 40: Imwitor®742: Miglyol812: EtOH, 34: 25.5: 25.5: 
15, w/w], formulation 3 [Solutol®HS 15: Imwitor®742: Miglyol®812: EtOH, 34: 25.5: 
25.5: 15, w/w]. Indomethacin was added (50 mg/ml). Hard gelatine capsules (size 0) 
from Capsugel Inc., Belgium, were filled with 0.5 ml formulation to achieve a dose of 
25 mg API per capsule. For the experiments with pure indomethacin, 25 mg of API 
were manually filled in each capsule. 
3.2.2.4 Saturation solubility 
Saturation solubility of indomethacin was determined in aqueous and physiologically 
representative media as well as in the three formulations. Sample with drug excess 
(n = 3) were equilibrated for 24 h in the corresponding media using a constant stirring 
(785 rpm) at 37 ± 0.5°C. Aliquots were taken after 24 h of equilibration, centrifuged 
with an Eppendorf Centrifuge 5415C (15 min, 14000 rpm) from Vaudaux-
Eppendorf AG, Switzerland, and the concentration of the clear supernatant was 
determined by HPLC. 
3.2.2.5 Dynamic laser light backscattering 
Dynamic laser light scattering is a technology in which a time correlation function of 
the scattered intensity is measured. The decay of this correlation function with time 
was used to calculate the diffusion coefficient of the particles, D. This property shares 
a mathematical relationship (Stokes-Einstein equation) with the hydrodynamic radius, 
R of a particle: 
  
R = kbT
6piηD
                                                                                                                 (3.1) 
Where kb is the Boltzmann constant, T the absolute temperature, and η is the viscosity 
of the continuous phase. The dispersion technology software 5.0 (Malvern 
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Instruments Ltd., United Kingdom) calculated for each measurement a Z-average 
value together with the polydispersity index (PDI). 
The instrument was a Zeta Sizer Nano ZS (Malvern Instruments Ltd., United 
Kingdom) having a 4 mW He-Ne Laser with a wavelength of 633 nm and the 
scattering signal was recorded at an angle of 173°. Measurements were conducted at 
ambient temperature. 
3.2.2.6 Dispersion/precipitation tests 
Dispersion/precipitation tests were conducted using the paddle method in an USP I/II 
apparatus (DT 600, ERWEKA GmbH, Germany). The dissolution media used were 
0.1 N HCl, phosphate buffer Ph.Eur. pH 6.8, containing NaCl, FaSSGF, and FaSSIF. 
The volume of the media was 500 ml, the velocity of stirring 100 rpm, and the 
temperature 37 ± 0.5°C. Samples (1 ml) were taken (n = 3) after 5, 10, 15 and 30 min, 
and after 1, 2, 4, and 6 h. After filtering the sample through a regenerated cellulose 
membrane filter with 0.45 µm pore size (SUN-SRi, United States), the concentration 
of dissolved compound was determined by HPLC. 
The flow-through tests were carried out with an USP IV apparatus (CE 7 smart, 
SOTAX AG, Switzerland) and performed as an open-loop setting. Each dissolution 
cell (internal diameter 22.6 mm) was charged with a ruby bead in the apex of the cone 
and glass beads above to generate a laminar flow. A dynamic media change was 
performed based on a physiologically motivated pH-cascade. pH-values and times 
were selected according to the pharmacokinetic modeling program Gastro Plus™ 
(Simulations Plus, Inc., United States): 0.1 N HCl (15 min), phosphate buffer pH 6.0 
(16 min), and phosphate buffer pH 6.8 (3 h 02 min). The flow rate was 8 ml/min. 
Samples were collected (n = 3) at predefined times, filtered, and subsequently assayed 
by HPLC. 
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3.2.2.7 Lipolysis test 
An aliquot of formulation (0.5 ml) was dispersed in 36 ml of FaSSIF at 37°C in a 
double-walled glass vessel. The solution was equilibrated for 15 min. By the addition 
of 4 ml pancreatin extract (1000 TBU/ml final concentration) and 5 mM calcium 
chloride dihydrate the lipolysis was started. Using 0.2 N NaOH the fatty acids 
released were titrated. Samples (4.4 ml) were taken (n = 3) after 5, 10, 15, 30, 45, and 
60 min. After sampling, lipase was inhibited by adding 40 µl 4-bromophenylboronic 
acid (0.2 g/ml methanol). The samples were centrifuged at 20°C at 34000 rpm for 
90 min in a Beckman L7 Ultracentifuge (Beckman Instruments, Inc., United States). 
The centrifuge tubes were Polyallomer Bell-Top Quick-Seal™ Tubes, size 
16 x 38 mm (Beckman Instruments, Inc., United States). Aqueous phase was collected 
to determine the concentration of indomethacin via HPLC. 
3.2.2.8 HPLC assay 
HPLC was performed on a LiChrospher®60, RP select B 125-4 (5 µm) column 
(Merck KGaA, Germany). The mobile phase consisted of 50 mM phosphoric acid and 
acetonitrile (40:60 v/v), the flow rate was 1 ml/min, and the detection wavelength was 
260 nm (Lunn and Schmuff, 1997-2000). 
3.3 Results and Discussion 
3.3.1 Solubility of indomethacin in different aqueous buffer systems, 
simulated gastro-intestinal fluids, and in formulations 
Table 3-2 shows the solubility of indomethacin, a poorly soluble, weakly acidic drug, 
in different aqueous buffer systems, in simulated gastro-intestinal fluids, and in 
formulations at 37°C. 
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Solubility of indomethacin in pH Solubility (µg/ml) 
Standard  
deviation 
   (%) 
    
Aqueous buffer systems    
 
   
Citrate buffer 4.0 1.55 3.9 
Citrate buffer 5.0 8.75 2.2 
Citrate buffer 6.0 77.58 2.6 
Phosphate buffer 7.0 569.66 8.4 
    
    
Gastro-intestinal fluids    
 
   
SGF 1.2 0.93 7.5 
FaSSGF 1.6 1.33 51.9 
FeSSIF 5.0 106.14 2.3 
FaSSIF 6.5 397.89 0.9 
SIF 6.8 516.2 1.6 
    
    
Formulations    
 
   
Formulation 1 - 71.67*103 2.5 
Formulation 2 - 74.63*103 2.6 
Formulation 3 - 76.47*103 5.7 
    
SGF: Simulated Gastric Fluid, FaSSGF: Fasted State Simulated Gastric Fluid, FeSSIF: Fed State 
Simulated Intestinal Fluid, FaSSIF: Fasted State Simulated Intestinal Fluid, SIF: Simulated Intestinal 
Fluid 
Table 3-2: Solubility of indomethacin in different aqueous buffer systems, in gastro-intestinal fluid, 
and in formulations at 37°C after 24 h 
As expected for a weak acid, the solubility at lower pH was clearly reduced as 
compared with the solubility of pH-values above the pKa. This dominant pH-effect 
was also observed comparing the solubilities in the simulated gastro-intestinal fluids. 
Under acidic conditions in simulated gastric fluid, only a small amount of 
indomethacin was dissolved. The solubility increased in all the other media with 
higher pH. Solubility of the API at equal pH was higher in the biorelevant media than 
in simple buffers due to the drug solubilization in mixed micelles (Galia et al., 1998). 
The effect of bile salt and lecithin was evident comparing the solubilities of citrate 
buffer at pH 5 and FeSSIF at pH 5, whereas an approximately tenfold increase of 
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solubility occurred. Finally, we also determined the solubility in the formulations at 
37°C to learn about differences. This initial drug solubility can be viewed as a starting 
solvent capacity of the formulation prior to the dispersion process. Substantial 
differences in the drug formulation solubility can influence the potential of a system 
to keep the drug solubilized. The results showed that all lipid-based systems had 
roughly similar equilibration solubility. All systems had an equal initial situation with 
respect to drug solubility and it would be the specific dispersion and lipolysis process 
that could make a difference regarding the fate of the formulations. 
3.3.2 Dilution tests  
Simple dilution tests primarily aim to characterize lipid-based formulations according 
to their type of self-emulsification. It is also of interest to check, if potential drug 
precipitation occurs. The ability to keep the drug solubilized in combination with a 
small final particle size can be viewed as positive indicators for viable lipid-based 
formulations (Pouton, 2000). Dilutions tests can therefore help screening initial 
formulation candidates. 
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SMEDDS formulation of  
indomethacin (50 mg/ml) API Dilution with 
Particle  
size 
Standard  
deviation 
Polydispersity  
index 
  water (nm) (%) (PDI) 
       
Formulation 1 N 1:10 29.4 3.7 0.7 
(semi-solid) Y  14.2 0.7 0.16 
 
N 1:20 16.8 0.6 0.23 
Gelucire®44/14  76% Y  13 0.8 0.07 
Transcutol®HP  19% N 1:50 13 0.0 0.05 
Labrafil®M-2125 CS 5% Y  13.2 0.8 0.2 
  N 1:100 13.2 0.8 0.07 
  Y  62.1 59.7 0.19 
       
Formulation 2 N 1:10 27.6 1.4 0.06 
(liquid)  Y  17.8 0.6 0.18 
 
N 1:20 27.2 0.7 0.03 
Cremophor®RH 40 34% Y  16.4 0.0 0.13 
Imwitor®742  25.5% N  1:50 28.5 0.7 0.02 
Miglyol®812  25.5% Y  17.5 0.6 0.12 
Ethanol  15% N 1:100 28.7 0.3 0.02 
  Y  20.6 0.5 0.11 
       
Formulation 3 N 1:10 49.6 3.0 0.23 
(liquid)  Y  258.7 0.6 0.58 
 
N 1:20 34.9 0.6 0.05 
Solutol®HS 15  34% Y  132.8 1.1 0.54 
Imwitor®742  25.5% N 1:50 47.4 1.9 0.2 
Miglyol®812  25.5% Y  22.6 0.9 0.27 
Ethanol  15% N 1:100 23.5 0.8 0.02 
  Y  27.4 0.7 0.15 
API: Y: yes, N: no 
Table 3-3: Particle size of the different SMEDDS in various dilutions, consider that all solutions were 
clear 
Table 3-3 shows that all formulations were SMEDDS, since they spontaneously 
formed transparent microemulsions upon aqueous dilution with a lipid droplet size of 
less than 50 nm (Gursoy and Benita, 2004). A previous work studied the evolving 
particle size of SMEDDS and outlined several influential parameters: the dilution 
factor, the medium, temperature, and formulation components (Ditner et al., 2009). In 
this study, the diluted systems without indomethacin reached very small particles 
already at a low dilution of 1:10. Microemulsions were obviously formed in a broad 
range along the dilution pathway, which can be called a robust dilution. 
EXPERIMENTAL SECTION 34 
 
 
Interesting was the interaction of the evolving particle size and the dissolved API. 
Gershanik already reported that interactions between formulation and indomethacin 
led to changed particles, which may be the consequence of a modified self-
emulsification process in the presence of the drug (Gershanik and Benita, 2000). This 
drug perturbation of the self-emulsification process resulted with formulations 1 and 2 
often in a smaller particle size than obtained with dilution of the pure vehicles. This 
was, however, different in case of formulation 3. Dilutions at 1:10 and 1:20 provided 
enlarged particles being rather small droplets of high polydispersity than micellar 
drug assemblies. However, all of these dilution samples were macroscopically 
transparent showing no drug precipitation. The specific drug-effects on the particle 
size did evidently not lead to a macroscopic event like a phase separation or the 
crushing out of drug. Advanced formulation assessment therefore required the 
conduct of more refined in vitro methods than simple dilution. 
3.3.3 Dispersion/precipitation tests 
The dispersion/precipitation tests using the paddle apparatus were performed in 
different media. Experiments were conducted using 0.1 N HCl as well as phosphate 
buffer pH 6.8. In addition, the same tests were also performed in biorelevant media 
FaSSGF and FaSSIF. Figure 3-1, Figure 3-2, Figure 3-3, and Figure 3-4 show the 
kinetic profiles. 
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Figure 3-1: USP II dispersion/precipitation at 37°C in 0.1 N HCl using 25 mg pure indomethacin or 
25 mg indomethacin in 0.5 ml formulation 
 
Figure 3-2: USP II dispersion/precipitation at 37°C in FaSSGF pH 1.6 using 25 mg pure indomethacin 
or 25 mg indomethacin in 0.5 ml formulation 
As expected for an acidic drug, the release of indomethacin in 0.1 N HCl was very 
poor. This was in contrast to the much faster and extensive release of the API from 
the lipid formulations. However, also the lipid systems displayed differences in this 
acidic environment. Formulations 2 and 3 displayed a high initial release rate with 
substantial variability of the drug concentrations. Both delivery systems had declining 
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drug concentrations after about 30 min and 1 h, which indicated the precipitation of 
drug. Formulation 1 was able to keep the drug in solution, which could be an 
advantage over other formulations that would require a redissolution of the drug in the 
intestine. 
It is important to better understand the ability of lipid-based systems to keep a drug in 
form. As previously reported by Pouton (Pouton, 2000; Pouton, 2008), the presence 
solubilized and type of cosolvent in the lipid-based formulations can drastically 
reduce their solvent capacity after aqueous dilution. Formulation 1 contained 
Transcutol®HP as a different cosolvent than EtOH that was present in formulations 2 
and 3. Since EtOH is a small, fast-diffusing molecule, it is possible that a faster 
depletion of the cosolvent occurred in the swollen micelles of formulations 2 and 3 
leading to a reduced ability to keep the drug solubilized. 
In FaSSGF, practically no release of indomethacin was observed from the 
conventional capsules containing the active compound alone (Figure 3-2). In contrast, 
the maximum dissolved drug from formulations 1 and 3 appeared after 1 h, in case of 
formulation 2 already after 30 min. Although the drug solubility in FaSSGF was 
higher than in 0.1 N HCl, all formulations exhibited drug precipitation. In the 
biorelevant FaSSGF, formulation 1 could not maintain the drug solubilized in contrast 
to its performance in 0.1 N HCl. After 6 h, only 1.2% of the total amount was 
dissolved in the biorelevant medium, whereas in the experiment using 0.1 N HCl, 
49.4% of indomethacin was still dissolved. It must be concluded that the components 
of FaSSGF substantially affected the dispersion and precipitation ability of this 
SMEDDS. The result also underpins the importance of media- and formulation 
specific effects that define the kinetic course of the dispersion (Charman et al., 1996; 
Kostewicz et al., 2001). It was remarkable to which extend the lipid formulations 
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were generally able to achieve a transient supersaturation in comparison with the pure 
drug. The acidic media were in that respect better suited to detect formulation 
differences than other media having higher equilibrium drug solubility. 
 
Figure 3-3: USP II dispersion/precipitation at 37°C in phosphate buffer pH 6.8 using 25 mg pure 
indomethacin or 25 mg indomethacin in 0.5 ml formulation 
 
Figure 3-4: USP II dispersion/precipitation at 37°C in FaSSIF pH 6.5 using 25 mg pure indomethacin 
or 25 mg indomethacin in 0.5 ml formulation 
In the experiments at higher pH, the results were less discriminating in comparison to 
the results in acidic environment. In buffer pH 6.8 (Figure 3-3), the formulations 
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reached the 90% level of solubilized API quickly (formulation 2 after 1 h, 
formulations 1 and 3 after 2 h), whereas the solubilized amount of pure indomethacin 
after 6 h was 70.9%. The results confirmed the difference between the pure drug and 
the lipid-based systems, but the latter formulations did not reveal substantial 
differences in this test. 
Dispersion/precipitation tests in FaSSIF pH 6.5 (Figure 3-4) showed a maximum of 
dissolved indomethacin in all formulations after 30 min, the maximum of pure drug 
appeared 2 h after the beginning of the experiment. Formulations allowed solubilizing 
nearly the total amount of API (98.6% to 100%), whereas 90.7% of the pure 
indomethacin went into solution. The increase of the solubility of the pure drug in 
comparison to the results in phosphate buffer pH 6.8 was due to the bile salt and 
lecithin in FaSSIF. Like with the phosphate buffer pH 6.8, also FaSSIF pH 6.5 was a 
medium in which the acidic drug alone reached comparatively high solubility values. 
Certainly, the expected medium in the intestine is less challenging for an acidic drug 
than the environment of the stomach. From this physiological viewpoint the question 
can be raised, what would happen, if the drug first enters an acidic environment 
followed by media that mimic the intestinal conditions. Such dispersion using a 
cascade of physiological pH changes was obtained from the USP IV experiments. 
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Figure 3-5: USP IV dispersion/precipitation at 37°C applying the pH cascade: 1) 0.1 N HCl (15 min); 
2) phosphate buffer pH 6.0 (16 min); 3) phosphate buffer pH 6.8 (182 min) using 25 mg pure 
indomethacin or 25 mg indomethacin in 0.5 ml formulation 
Figure 3-5 shows the results of the physiologically motivated flow-through cell. 
During the first 20 min, no indomethacin went into solution, if only pure API was 
used. Afterwards, indomethacin dissolved slowly. Following 3.5 h, 43.5% of the drug 
was dissolved. Dispersion of lipid-based formulations was in contrast much faster. In 
the course of the experiment, we observed a clear difference between the dispersion of 
the formulations. Formulation 1 exhibited a superior kinetic course regarding drug 
solubilization, whereas the formulations 2 and 3 reached a comparatively lower 
concentration plateau. 
The dissolution investigations using the flow-through method with the USP IV as 
well as USP II instruments showed a clear difference between the dissolved amount 
of capsules with pure API and the lipid self-dispersing formulations of indomethacin. 
During the first 15 min in the USP IV test pure drug/formulations were exposed to 
0.1 N HCl as in the experiments using the USP II apparatus. In both cases, no pure 
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drug went in solution. The rank order within the formulations was similar. Following 
a continuous change of the medium via pH 6 the drug/formulations were exposed to 
phosphate buffer at pH 6.8. The release of pure drug was always smaller than that of 
formulations. Regarding the formulations, a clear difference could be observed using 
these in vitro tests. The flow-through method was the only experiment in our series, 
which simulated the important transfer aspect from acidic to more neutral conditions. 
Due to this fact, that the API as well as the formulations were exposed to acidic and 
neutral conditions, this results obtained a special significance.  
Interestingly, differences between formulations became apparent only under certain 
experimental test conditions of pH and dynamic media change. Although the effects 
of these conditions on dissolution of the drug alone are predictable, it is difficult to 
foresee their possible interactions with the more complex formulation systems. 
Additionally, the studied formulations differed in practically all of their components, 
which makes it difficult to clearly interpret their specific behavior. Therefore, the 
observed effects may be the result of confounding factors originating from the studied 
drug delivery systems and the experimental conditions. To clearly identify the 
individual contribution of formulation factors and test conditions on the release 
behavior, many additional experiments would be needed. Such test factors may 
include the individual excipients, the additives in the media as well as defined levels 
of hydrodynamic test conditions. In parallel to such a mechanistic investigation the in 
vivo relevance of these experimental findings should be demonstrated.  
Additionally, the in vivo situation involves the digestion process of formulations. This 
aspect was considered following lipolysis tests. 
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3.3.4 Lipolysis in biorelevant media 
Figure 3-6 shows the results of drug dispersion using a lipolysis assay. After 5 min of 
lipolysis, formulations 1 and 2 reached the maximum of dissolved indomethacin 
(69.6% and 75.7%, respectively). The maximum of dissolved amount API of 
formulation 3 was obtained after 30 min. We noticed a minimal reduction of dissolved 
amount during the continuation of the lipolysis. Pure indomethacin solubilized more 
slowly. After an increase to 44.8% during the first 5 min, the dissolved amount raised 
to 63.9% at the end. 
 
Figure 3-6: Lipolysis at 37°C in FaSSIF pH 6.5 using 25 mg pure indomethacin or 25 mg 
indomethacin in 0.5 ml formulation 
Once again the lipid-based formulations displayed higher solubilized drug 
concentrations than the pure drug in a capsule. However, this concentration gap was 
diminished following longer observation times in the experiment. A clear distinction 
of the lipid formulations was not exhibited, but some tendencies were observed. 
Interestingly, it was not formulation 1 that showed superior drug release, but in this 
test formulation 3 had at least following 30 min the highest drug concentrations. The 
dispersion behavior of the formulations was obviously affected by the lipolysis. 
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Effects cannot only happen on the level of the surface-active lipolytic products, but 
also by means of a lipolysis inhibition of the surfactant (Hutchison, 1994). These 
specific interactions of the formulation with the lipolysis were shown to be of 
relevance for the assessment of the formulations. Such effects of formulation 
digestion are important, as it was the case for considering media of different pH-
values. 
Regarding the presently used lipolysis test, the different hydrodynamics in 
comparison to compendial equipment must be mentioned. This aspect shows that 
currently all lipolysis tests are still research-oriented and there is a need to develop a 
compendial version in the future. Thus, the design would have to be standardize and 
the test conditions must be validated. 
Even though the present study was focused on the comparison of in vitro tests and 
indomethacin was selected as model acid, the aspect of in vivo relevance should be 
discussed. Poorly soluble acids can exhibit incomplete drug absorption (Yazdanian et 
al., 2004). The reduced absorption can be problematic itself as well as the variability 
that usually occurs in parallel. As it was shown earlier the effect of incomplete drug 
absorption of a poorly soluble acid is depending on the dose (Kuentz, 2008). This 
problem of administering high doses is particularly a problem in the area of 
toxicological formulations. Poorly soluble drugs therefore provide an especially 
critical formulation task for the preclinical drug development phase. In case of 
indomethacin, rat studies at higher doses showed clearly increased absorption of a 
self-emulsifying system compared with a methyl cellulose suspension (Kim 
and Ku, 2000). Such in vivo results confirm the potential of lipid-based systems to 
increase drug absorption of poorly soluble acids. Differences among formulations are 
expected to be related to their ability to keep the drug in solubilized form. Our in vitro 
43 EXPERIMENTAL SECTION 
 
 
results were able to show formulation effects in that respect. Furthermore, we found 
that currently a single compendial test may not be sufficient to fully characterize the 
dispersion behavior of a lipid formulation. 
3.4 Conclusions 
Based on the results of the different in vitro tests, we conclude that the combination of 
different modern in vitro tests provide the means to estimate the potential of new 
lipid-based formulations for poorly soluble acids. Since the pharmaceutical industry 
requires a fast and efficient formulation development, it is important to learn about the 
minimally required formulation tests. The solubilizing capacity of formulations 
depends on the components of the formulations, the physicochemical properties of the 
pharmaceutical ingredients, and the environment in the gastro-intestinal tract. The 
formulations of a poorly soluble acid may be screened by simple dilution tests, but 
promising candidate formulations must be further explored in dispersion/precipitation 
experiments. A discriminating acidic medium can be conducted together with a 
lipolysis test. As an option, the dispersion/precipitation test in the acidic medium can 
be replaced by a physiologically motivated flow-through test. Further research is 
needed to develop the most effective in vitro tests for lipid-based systems and also to 
learn about their relevance for in vivo. A proper in vitro assessment of SMEDDS is 
not only meaningful for administration in humans, but is also important with respect 
to preclinical formulations. 
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4 FENOFIBRATE PRECIPITATION IN THE 
SIMULATED INTESTINE – IN VITRO STUDY OF 
POLYSORBATE 80 EFFECTS ON NUCLEATION 
AND PARTICLE GROWTH IN BIORELEVANT 
MEDIA USING FBRM 
4.1 Introduction 
Since the number of poorly water-soluble drug is increasing, a deepened 
understanding of precipitation processes under physiological conditions is needed. 
New insights would facilitate the development of suitable formulation principles for 
drug solubility enhancement in the gastro-intestinal tract. Therefore, for a reliable 
prediction of the precipitation behavior of a drug, the knowledge about precipitation 
processes including the whole gastro-intestinal passage has to be improved.  
To gain new insights into drug precipitation in biorelevant media, suitable inline tools 
are required for monitoring number, shape, and size of the arising precipitates. Gao et 
al. recently pioneered using FBRM in monitoring drug precipitation (Gao et 
al., 2009). The FBRM technique was used before in scientific applications other than 
in vitro testing (Chew et al., 2007; Hermanto et al., 2010; Leyssens et al., 2011). This 
tool appeared to be very promising for in vitro precipitation analysis. However, Gao 
et al. limited their study to drug precipitation in water, but more physiological 
conditions would be of more interest. 
The aim of this work was to monitor the influence of PS80/EtOH formulations as well 
as the micelles and vesicles of the biorelevant media on precipitation processes of our 
BCS II model drug fenofibrate in the simulated intestine, after the passage through the 
stomach. All the experiments were performed in mixtures of water, FaSSGF, and 
FaSSIF V2. As analytical inline tool FBRM was used for the first time in biorelevant 
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media. The findings were complemented with additional measurements using the 
inline analytical tool Raman spectroscopy. 
4.2 Materials and Methods 
4.2.1 Materials 
Fenofibrate, ammonium acetate, maleic acid, sodium chloride, and sodium hydroxide 
were purchased from Sigma-Aldrich GmbH, Switzerland. Pepsin and PS80 were 
obtained from Hänseler AG, Switzerland, sodium taurocholate was purchased from 
Prodotti Chimici e Alimentari S.p.A., Italy, and the egg lecithin Lipoid E80 was 
obtained from Lipoid GmbH, Germany. Finally, EtOH and acetonitrile HPLC grade 
were supplied from Mallinckrodt Baker, Inc., United States. 
4.2.2 Methods 
4.2.2.1 Preparation of formulations 
Six formulations consisting of PS80 and EtOH were prepared. Table 4-1 shows the 
composition of the formulations, in which fenofibrate was solubilized in the following 
concentrations:  44.0 mg/ml, 81.6 mg/ml, or 118.8 mg/ml.  
Formulation Polysorbate 80  
(ml) 
Ethanol  
(ml) 
1 0 0.250 
2 0.050 0.200 
3 0.083 0.167 
4 0.125 0.125 
5 0.188 0.063 
6 0.250 0 
Table 4-1: Compositions of the formulations 
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4.2.2.2 Preparation of simulated gastro-intestinal fluids 
FaSSGF and FaSSIF V2 were used as biorelevant media. They were prepared as 
previously reported based on the components described in Table 4-2 (Jantratid et 
al., 2008). 
 FaSSGF FaSSIF V2 
Sodium taurocholate (mM) 8*10-2 3 
Lecithin (mM) 2*10-2 0.2 
Maleic acid (mM) - 19.12 
Sodium chloride (mM) 34.2 68.62 
Sodium hydroxide (mM) - 34.8 
Pepsin (µM) 1.24 - 
FaSSGF: Fasted State Simulated Gastric Fluid, FaSSIF V2: Fasted State Simulated Intestinal Fluid V2 
Table 4-2: Compositions of biorelevant media 
4.2.2.3 Determination of solubilities and definition of supersaturation 
To calculate the supersaturation values, the equilibrium solubilities were determined 
in the formulations, in the pure biorelevant media, and in the biorelevant media with 
added formulations. Drug excess was added to three samples per mixture that were 
equilibrated under intensive magnetic stirring at 37 ± 0.5°C. Aliquots were taken after 
24 h of equilibration and subsequently centrifuged for 15 min at 14000 rpm using an 
Eppendorf Centrifuge 5415C from Vaudaux-Eppendorf AG, Switzerland. Finally, the 
clear supernatant was diluted with EtOH (factor 90 in case of pure formulations and 
factor 1.5 in the samples containing biorelevant media) and the concentrations of 
these solutions were determined by HPLC. The measurements were performed on a 
LiChrospher60, RP select B 125-4 (5 µm) column (Merck KGaA, Germany). The 
mobile phase consisted of 25 mM ammonium acetate buffer pH 3.5 and acetonitrile 
(35:65 v/v). Samples of 20 µl were injected and analyzed at flow rate 1 ml/min, and 
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the detection wavelength was 287 nm (Thi et al., 2009). A calibration line was 
determined in the concentration range between 0.070 mg/ml and 1.115 mg/ml, which 
provided a R2 of higher than 0.99. 
 
Absolute supersaturation SSabs at the beginning of the precipitation monitoring was 
calculated using equation 4.1: 
  
SS = S
Seq                               
(4.1) 
where
 
S is the corresponding fenofibrate concentration (597 µg/ml, 410 µg/ml, 
221 µg/ml)  and Seq is the equilibrium solubility in the final mixture (FaSSGF, 
FaSSIF V2, API, PS80, EtOH, and water). 
4.2.2.4 Experimental procedure of the in vitro precipitation test 
In a 50 ml beaker, the reaction mixture was prepared as shown in Table 4-3. Detailed 
determination of the amounts of media and formulations is described in the appendix, 
section 9.1.1. 
 
Time 
(min) 
Activity 
 
-2 Start medium: 5.5 ml FaSSGF, 37°C 
-1 Addition of 11.0 ml water, room temperature 
-0.5 
Addition of 0.25 ml formulation (options see Table 4-1) 
containing fenofibrate (44.0 mg/ml, 81.6 mg/ml, or 
118.8 mg/ml), room temperature 
Start  Addition of 33.0 ml FaSSIF V2, 37°C, and 
of the experiment  beginning of precipitation monitoring using FBRM 
FaSSGF: Fasted State Simulated Gastric Fluid, FaSSIF V2: Fasted State Simulated Intestinal Fluid V2 
Table 4-3: Experimental procedure of the in vitro precipitation test 
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The solution was mixed with an angular stirrer at 400 rpm and temperature was kept 
constant at 37°C using EasyMax 102 (Mettler Toledo International, Inc., 
Switzerland), while precipitation was monitored using a PI-8/91 LASENTEC® FBRM 
probe (Mettler Toledo International, Inc., Switzerland). Measurements were recorded 
every two seconds and data were binned into 100 logarithmically-spaced channels in 
the range from 1 µm to 1000 µm. As additional monitoring tools a Raman 
spectrometer was used. Raman spectra were determined with a Raman RXN2 
spectrometer (Kaiser Optical Systems, Inc., United States). A laser emitting at the 
wavelength 785 nm and a detector of the type DV 420-OE were used to record spectra 
over the range from 100 cm-1 to 1890 cm-1. To avoid the influence of the daylight on 
the measurements, the reaction vessel was completely covered with aluminum foil.  
4.2.2.5 Analysis of data 
Analysis of the variance (ANOVA) was calculated using the program Statgraphics 
Centurion XV ed. Professional from StatPoint Technologies, Inc., United States. 
Significance was assumed for those factors that demonstrated a probability p-value of 
less than 0.05. 
4.3 Results and Discussion 
4.3.1 Preliminary tests 
4.3.1.1 Evolution of FBRM counts/s during preparation of biorelevant media 
The FBRM signal was studied during preparation of the biorelevant media. Figure 4-1 
indicated that most of the FBRM counts/s were given after the addition of lecithin. 
Before, the FBRM counts/s were generally low because all other components were 
well soluble in water. In contrast, lecithin is a water insoluble substance. In case of the 
preparation of FaSSGF (Figure 4-1a), the slight increase of FBRM counts/s was due 
to the addition of lecithin that was expected to form vesicles below the critical 
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concentration of mixed micelles. Regarding the preparation of FaSSIF V2 (Figure 
4-1b), it is known that bile salts and lecithins form mixed micelles (Small et al., 
1966). However, the elevated FBRM counts/s were most likely due to aggregated 
vesicles or other larger colloids. It was an interesting finding that the FBRM counts/s 
of the biorelevant media mixture decreased following addition of the formulation 
components. This effect will be discussed later in some more details. 
 
                                                                               250          Addition of lecithin 
                Addition of lecithin                                200 
                                                                               150 
                                                                               100 
                                                                                 50 
                                                                                   0 
                                                                                                       30            60  
                                                                                            Time (min)                                             
a)                 b) 
Figure 4-1: FBRM counts/s as a function of time during preparation of 50 ml medium, 37°C:              
a) FaSSGF, b) FaSSIF V2 
As shown in Figure 4-2 the FBRM counts/s of the simulated stomach-intestine-water 
mixture were conserved after mixing these liquids and they were proportional to the 
volumetric ratios. Assuming an average FBRM counts/s for the FaSSGF of 190 and 
for the FaSSIF V2 of 320 (FBRM counts/s in water were 0) and knowing that the 
volumetric ratio stomach:water:intestine was 1:2:6, then the weighted average of the 
simulated biorelevant media mixture was about 234 FBRM counts/s which 
corresponded to the FBRM measurements reported in Figure 4-2. It can be concluded 
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that the FBRM sensor is a suitable tool to monitor the properties of the biorelevant 
media so that reproducible quality of the media was assured for their use in the 
following drug precipitation experiments.  
 
Figure 4-2: FBRM counts/s of the individual biorelevant media, 37°C: a) FaSSGF, b) FaSSIF V2, 
c) simulated biorelevant media mixture (composition of the biorelevant media mixture see Table 4-3) 
4.3.1.2 Evaluation of the effect of PS80 on the mixture of biorelevant media 
with respect to the FBRM measurements 
 
Prior to the drug precipitation experiments, the changes in the FBRM signals due to 
the addition of pure formulations to the biorelevant media mixture were analyzed. 
Figure 4-3 shows that the number of FBRM counts/s specific for the biorelevant 
medium was around a 250 FBRM counts/s baseline. Another observation was that, 
with one exception, all the biorelevant media samples showed similar number of 
FBRM counts/s, which demonstrated the good reproducibility of the medium 
preparation. Interesting was the decreasing signal of the FBRM counts/s upon 
addition of formulation. The effect was not seen by addition of pure EtOH so the 
decreasing numbers of FBRM counts/s were due to PS80 alone. 
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Formulation PS80 EtOH 
   (ml)       (ml) 
1     0 0.250 
2  0.050 0.200 
3  0.083     0.167 
4  0.125 0.125 
5  0.188 0.063 
6  0.250     0 
 
 
Figure 4-3: Simulated biorelevant media mixture, 37°C: FBRM counts/s of the biorelevant media 
mixture after addition of 0.25 ml formulation (options see Table 4-1) 
To better understand the changes of FBRM counts/s in presence of PS80, Figure 4-4 
plots the different chord length distributions (CLDs) before and after the addition of 
formulation 5 (0.188 ml PS80, 0.063 ml EtOH). It was shown that besides the 
decrease of the number of FBRM counts/s the mean of the CLD shifted towards larger 
values. This behavior was observed in all experiments.  
PS80 is obviously interacting with the colloidal structures of the biorelevant medium. 
A reduction of aggregated colloids in favor of mixed micelles could explain the 
reduction of FBRM counts/s, since it was previously shown that polyoxyethylene 
chains of polysorbates reduce particle aggregation (Yanasarn et al., 2009). The 
formed mixed micelles were too small for detection using FBRM. Such interaction of 
the excipient PS80 with bile salts and lecithins is of interest with respect to drug 
solubilization. However, changes over time may influence accurate determination of 
FBRM counts/s in experiments with little precipitation. Experiments with 
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comparatively high amounts of precipitated drug are expected to be less affected by 
such changes. 
 
 
 
Figure 4-4: Simulated biorelevant media mixture, 37°C: FBRM chord length distributions before and 
30 min after the addition of formulation 5 (0.188 ml PS80, 0.063 ml EtOH)  
4.3.1.3 Effects of formulations on particles/vesicles of the biorelevant media 
mixture using Raman spectroscopy 
The influence of formulation 5 (0.188 ml PS80, 0.063 ml EtOH) on the biorelevant 
media mixture was also analyzed using Raman spectroscopy, since it is known that 
particle size can affect the Raman intensity. It was found that after the addition of the 
formulation the integrated intensity between 1610 cm-1 and 1670 cm-1 changed from 
2650 to 2735, which is about 3%. In order to investigate whether this change was due 
to a change of the number of lecithin micelles or due to the spectral characteristics of 
the PS80/EtOH formulation, the same experiment was conducted in pure water 
instead of biorelevant medium. It was found that the Raman intensity in the same 
range was also increased by 3%; therefore, it was concluded that the Raman 
measurements were only influenced by the addition of PS80/EtOH, while possible 
changes related to lecithin were not detectable. 
                                                            10                                                   100 
Chord length (µm) 
before 
FB
R
M
 
co
u
n
ts
/s 
30 min 
after 
   
13 
 
10 
 
  8 
 
  5 
 
  3 
 
  0 
 
 
  addition of  
formulation 5 
53 EXPERIMENTAL SECTION 
 
 
4.3.2 Fenofibrate solubility and supersaturation levels 
Equilibrium solubilities of fenofibrate were determined systematically in the pure 
formulations as well as in the biorelevant media with and without formulations. 
Figure 4-5 shows that equilibrium solubilities in the formulations differed 
considerably from that in pure EtOH. Fenofibrate equilibrium solubility in pure EtOH 
at 37°C was 50.29 ± 3.61 mg/ml. Compared to the value of 1 mg/ml published by 
Cayman Chemicals, it was much higher.  However, as soon as PS80 (0 ml to 0.25 ml) 
was added, equilibrium solubilities at 37°C increased in the range of 101 mg/ml to 
127 mg/ml. Among the PS80-containing formulations, increasing amounts of 
surfactant were only slightly increasing equilibrium solubilities (Figure 4-5a). In 
literature, a broad range from 0.7 mg/ml to 171 mg/ml of fenofibrate solubilities in 
PS80 at room temperature was reported (Mongkonwattanaleela et al., 2010; Patel and 
Vavia, 2007), while in our experiments an equilibrium solubility of 121 mg/ml was 
found.  
Solubility in water was found to be 0.4 ± 0.0 µg/ml. This value was close to the 
equilibrium solubility at the same temperature of 0.3 ± 0.0 µg/ml reported by Vogt et 
al., 2008. Compared to pure water the micelles of the biorelevant media enhanced 
equilibrium solubility at 37°C only slightly up to 0.7 ± 0.0 µg/ml.  
As soon as PS80 was added, equilibrium solubilities in the biorelevant media mixture 
increased. Figure 4-5b depicts the linearity of the equilibrium solubilities as a function 
of the PS80 volumes. The formulations contained varying amounts of PS80 and 
EtOH. The latter was either acting at the interface/headgroup region of the micelles or 
was expected to reside in the water phase (de Campo et al., 2004). Since the 
contribution of EtOH to drug solubility at 37°C was low (see intercept of Figure 
4-5b), the effect of EtOH was neglected. The solubility increase was the outcome of 
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drug solubilization in colloids. However, the approximate linearity of the equilibrium 
solubilities as a function of the PS80 volumes in the biorelevant media indicated that 
solubilization was mainly due to micelle formation (Rangel-Yagui et al., 2005).  
Despite the moderate influence of PS80 on drug solubility in the formulation, the use 
of relatively high amounts of PS80 was appropriate, because these formulations were 
able to enhance drug solubility in biorelevant media. Therefore, our mixtures of PS80 
and EtOH provided good model systems for in vitro drug precipitation studies. 
 
Figure 4-5: a) Fenofibrate equilibrium solubilities at 37°C in formulations (options see Table 4-1), 
b) Fenofibrate equilibrium solubilities at 37°C in 49.5 ml biorelevant media mixture including 0.25 ml 
formulation (options see Table 4-1), c) supersaturation as a function of the API/PS80 ratio 
In a next step, supersaturation values of the formulations as well as of the 
formulations in the biorelevant media were calculated, since they are the driving 
forces of precipitation. A supersaturated solution is in a thermodynamically unstable 
state. To reach the thermodynamic equilibrium solubility, precipitation occurs 
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(Brouwers et al., 2008). In our work, supersaturation was influenced by the drug 
concentration and by the amount of PS80 in the formulation. In Figure 4-5c 
supersaturation is depicted as a function of the API/PS80 ratio and linearity was 
demonstrated. An enhancement of PS80 and/or a reduction of the drug concentration 
resulted in a lower supersaturation and therefore should reduce the precipitation 
potential. Thus, for the formulation development it seems useful to select a 
composition with respect to targeting low supersaturation levels. 
4.3.3 Fenofibrate precipitation in the simulated intestine monitored 
using FBRM 
4.3.3.1 FBRM analysis of fenofibrate precipitation in simulated intestinal 
medium 
Drug precipitation in biorelevant medium was monitored using FBRM. In all 
measurements, the probe was placed at exactly the same position, since it was 
previously shown that the results are sensitive to the location of the probe (Barrett and 
Glennon, 1999). Three drug concentrations in six formulations, including different 
amounts of PS80, were tested. The simplicity of the formulation compositions 
allowed the evaluation of the influence of different amounts of PS80 on fenofibrate 
precipitation. In addition to the measurements in biorelevant media, the precipitation 
behavior of formulation 4, including 118.8 mg fenofibrate/ml, was monitored in pure 
water. Figure 4-6, Figure 4-7, and Figure 4-8 show the FBRM trends of the three drug 
concentrations in all the formulations in the range from 1 µm to 20 µm as a function 
of time. 
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Figure 4-6: 49.5 ml biorelevant media mixture, 37°C: FBRM counts/s in the range from 1 µm to 
20 µm as a function of time, 44.0 mg drug/ml formulation 
 
Figure 4-7: 49.5 ml biorelevant media mixture, 37°C: FBRM counts/s in the range from 1 µm to 
20 µm as a function of time, 81.6 mg drug/ml formulation 
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Figure 4-8: 49.5 ml biorelevant media mixture, 37°C: FBRM counts/s in the range from 1 µm to 
20 µm as a function of time, 118.8 mg drug/ml formulation 
Considering all three drug concentrations, the drug in pure EtOH precipitated 
extensively (Figure 4-6, Figure 4-7, Figure 4-8). Apparently, EtOH was not able to 
prevent or prolong precipitation. Moreover, bile salt and lecithin in the biorelevant 
media were also not able to inhibit or reduce precipitation and particle growth in 
absence of PS80.  
As soon as PS80 was added to the formulation, precipitation still occurred, but to a 
lesser extent. Interesting was the comparison of drug precipitation in water (black 
curve) and biorelevant media (red curve) using formulation 4 (0.125 ml PS80, 
0.125 ml EtOH, drug load of 118.8 mg/ml). In pure water, induction time was much 
higher and the number of FBRM counts/s after 45 min was lower (Figure 4-8). In 
contrast to the pure water, the colloids of the biorelevant media were likely to 
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promote hetergeneous nucleation. Moreover, it was shown earlier that precipitates 
were stabilized by adsorbing surfactants (Odian, 2004). It might be that lecithin in 
biorelevant media were stabilizing the evolving nuclei and therefore were causing 
accelerated drug precipitation.  
Induction time in the biorelevant media mixture was determined considering number 
of particles in the range of 1 µm to 20 µm. For the evaluation of the influence of drug 
concentration and formulation composition on the induction times, a multifactorial 
ANOVA was performed. Drug concentration in the formulations showed no 
significant influence on the induction time. In contrast, the analysis indicated a 
significant influence of the formulation composition on the induction time (p < 0.02, 
confidence level of 95 %). It can be concluded that with increasing amounts of PS80, 
it was possible to enhance the induction time.  
One has to keep in mind that nucleation time detection was specific for the FBRM 
measurements and probably was monitored with some retardation. The FBRM probe 
is able to detect particles starting from a size of around 1 µm and therefore particles 
with a size below this limit were not detected (Kee et al., 2011).  
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Figure 4-9: Biorelevant media mixture, 37°C: maximum FBRM counts/s as a function of 
supersaturation 
As depicted in Figure 4-9, there was a  tendency of increasing number of maximum 
FBRM counts/s with enhanced supersaturation regarding the FBRM counts/s in the 
range of 1 µm to 20 µm as well as in the range of 1 µm to 1000 µm. To determine 
significant influences, a multifactorial ANOVA was performed. Drug concentration 
had no significant influence on the maximum number of FBRM counts/s, but the 
amount of PS80 influenced this value significantly (p < 0.0001, confidence level of 
95 %).  
The FBRM counts/s showed no further changes after 60 min and 90 min, indicating 
an equilibrium state. Such equilibrium did not only mirror drug precipitation 
processes but also aggregation of the evolving particles.  
It was mentioned before that precipitates of poorly water-soluble drugs are often 
critical for drug absorption. Therefore, it would be desirable to keep drugs in a 
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solubilized state during the whole gastro-intestinal passage. If preciptiation still 
occurs, it seems preferable to enhance induction time to high levels and to reduce the 
maximal number of FBRM  counts/s significantly. The tested formulations were not 
able to keep fenofibrate in a solubilized state over the whole simulated gastro-
intestinal passage.  However, the tested formulations including PS80 were able to 
enhance drug solubility as well as induction time and to reduce maximal number of 
counts/s. Based on these results, it appeared possible to enhance fenofibrate 
absorption under fasted state conditions by oral intake of the drug in PS80/EtOH 
formulations. However, this assumption would have to be confirmed by in vivo 
experiments. 
4.3.3.2 The use of FBRM for monitoring needle like fenofibrate precipitates  
Fenofibrate precipitates appeared needle-shaped and therefore requested a special 
analytical procedure regarding nucleation and growth processes. Data analysis for the 
evaluation of the mode and the range of the FBRM counts/s was based on the 
suggestions of a recent work by Leyssens et al., 2011. To investigate the final shape 
of particles, offline microscopic images were taken at indicated time intervals shown 
in Figure 4-10. The next step was to determine the size range of the needles using the 
offline pictures (Table 4-4). Based on these results, it was possible to select the size 
ranges for the evaluation of different crystallization parameters.  
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 Length 
[µm] 
Width 
[µm] 
Sample 1 at 29.5 min   
Crystal 1 406 29 
Crystal 2 286 17 
Crystal 3 7 5 
Sample 2 at 34.5 min   
Crystal 1 19 7 
Sample 7 at 180 min   
Crystal 1 11 4 
Table 4-4: Dimension of the needle-shaped fenofibrate precipitates 
Based on these results, it was concluded that the needle diameter and the number of 
needles can be monitored by FBRM using the unweighted (no wt) mode of the FBRM 
counts/s in the 1 µm to 20 µm range (Figure 4-10, experiment in water at 37°C, 
0.125 ml PS80, 0.125 ml EtOH, including 118.8 mg/ml API). Furthermore, the needle 
length was represented by the mode of the square-weighted (sqr wt) FBRM counts/s 
in the 21 µm to 600 µm range.  
As depicted in Figure 4-11, the images taken at 29.5 min (formulation 4, 0.125 ml 
PS80, 0.125 ml EtOH, drug load of 118.8 mg/ml, added to water at 7 min 38 s) show 
few large crystals. Due to the large supersaturation these few needles grew to particles 
in a range from 300 µm to 400 µm in a rather short time. At around 35 min, the 
images show more small needles besides the big particles, which was considered to be 
a sign of secondary nucleation. In this case the initial particles provided additional 
surface area to promote secondary nucleation, which proceeded up to about 40 min. 
Subsequently, the median in the 21 µm to 600 µm range increased indicating a growth 
and/or agglomeration driven process. At the same time the FBRM counts/s in the 
1 µm to 20 µm range decreased, which was possibly due to dissolution and/or particle 
growth/agglomeration. 
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After 50 min the square-weighted median in the 21 µm to 600 µm range became 
constant, which indicated that the aggregates reached an equilibrium size for the 
considered size fraction and selected stirring conditions. However, after this time 
point the median decreased indicating the formation of smaller particles. At the same 
time, the FBRM counts/s in the 1 µm to 20 µm range increased, while the FBRM 
counts/s in the square-weighted range of 21 µm to 600 µm decreased, leading to the 
conclusion that a breakage/disagglomeration took place. This conclusion is also 
supported by the images taken after 128 min.  
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Figure 4-10: Water, 37°C, addition of formulation 4 (0.125 ml PS80 and 0.125 ml EtOH, drug load 
118.8 mg/ml) after 7 min 38 s: offline microscopy images taken during experiment 
29.5 min 
34.5 min 
40.5 min 
  49 min 
    128 min 
     80 min 
    180 min 
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   no wt: unweighted mode, sqr wt: square-weighted mode  
Figure 4-11: Water, 37°C, addition of formulation 4 (0.125 ml PS80 and 0.125 ml EtOH, drug load 
118.8 mg/ml) after 7 min 38 s: FBRM trends for analyzing needle-shaped fenofibrate precipitates 
4.3.4 Investigation of possible occurrence of polymorphs during 
fenofibrate precipitation and the influence of reaction mixture 
properties on the Raman signal 
According to Heinz et al. specific peaks of the Raman spectra between 1660 cm-1 and 
1560 cm-1 can be used to identify the crystalline form of fenofibrate precipitates 
(Heinz et al., 2009). Figure 4-12 shows the time-evolution of the Raman spectra 
(water spectrum subtracted from the measurement and PS80 signal was not 
significant) during the precipitation process and it was concluded that the precipitates 
were crystalline. Analysis of the full Raman spectra did not show any sign of the 
appearance of other polymorphs.  
To investigate the influence of solid concentration and crystal size on the intensity of 
the Raman spectra, the integrated intensity value in the range from 1602 cm-1 to 
1595 cm-1 is plotted in Figure 4-13. It was observed that upon the addition of the 
formulated API at 7 min there was an intensity threshold, which could be due to 
partial precipitation. This phenomenon could be an indicator for a higher sensitivity of 
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the Raman probe compared to the FBRM probe, since the latter showed no signal 
around 7 min. The large peak at 40 min was due to sampling. The reason for the 
sudden decrease of intensity after 60 min remained unclear, since FBRM data showed 
no major change in the sample properties. The monotonically increasing trend after 60 
min was attributed to enhanced diffuse reflectivity of the reaction mixture, which was 
the result of small particles generated during the breakage process. 
 
Figure 4-12: Water, 37°C, Raman spectra at three time points for the identification of the solid-state 
form of fenofibrate precipitates 
 
Figure 4-13: Water, 37°C: Integrated Raman spectrum between 1602 cm-1 and 1595 cm-1 
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4.4 Conclusions 
The nonionic surfactant PS80 in combination with EtOH was used as a potential 
precipitation inhibitor of the model drug fenofibrate. Precipitation was monitored in 
the simulated intestine using inline FBRM. The method was successfully introduced 
and it was possible to differentiate between heterogeneous nucleation and particle 
growth. The colloids in the biorelevant medium, interacting with PS80, were 
promoting drug precipitation compared to the results in pure water. Higher amounts 
of PS80 in the formulation had a significant influence on induction time and maximal 
number of FBRM counts/s. Using Raman spectroscopy, polymorphism of the 
precipitates was ruled out.  
FBRM analysis in simulated intestinal media proved to be a suitable tool for in vitro 
studying excipient effects and to provide a deepened understanding of fenofibrate 
nucleation and growth processes under simulated physiological conditions. Thus, 
formulation development can be guided by such novel in vitro tests. However, the 
obtained ranking of formulations may be confirmed by subsequent in vivo studies.  
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5 ADVANCING IN VITRO DRUG PRECIPITATION 
TESTING: NEW PROCESS MONITORING TOOLS 
AND A KINETIC NUCLEATION AND GROWTH 
MODEL 
5.1 Introduction 
New drug candidates in pharmaceutical development are often poorly water-soluble 
compounds. This leads to challenges in selecting the right formulation principle that 
on the one hand brings the drug into solution and on the other hand also keeps it in the 
solubilized state during the entire gastro-intestinal passage. The aqueous solubility is 
hereby influenced by the physicochemical nature of the compound. Therefore high 
lipophilicity or comparatively low lipophilicity in combination with a predominant 
hydrophobicity can result in poor solubility. 
Moreover, drug ionization plays an important role. If the pH is below the pKa, the 
solubility of weak bases is high in comparison to pH-values exceeding the pKa. 
Under physiological conditions, drugs move from acidic environment in the stomach 
to a pH of about 6.5 in the upper intestine, rendering weak bases prone to 
precipitation under these conditions. This relevant pH-change during the gastro-
intestinal passage is influenced by food, concomitant treatment with antacids and age 
(Badawy et al., 2006; Blum et al., 1991; Charman et al., 1997; Russel et al., 1994). 
A biorelevant transfer test is a useful tool to simulate such precipitation processes in 
vitro. In the literature different transfer tests were reported that describe pumping of 
the acidic medium containing solubilized drug into the neutral intestinal medium (Gu 
et al., 2004; Kostewicz et al., 2004; Sugawara et al., 2005; Zhou et al., 2005). Besides 
this transfer, the composition of the media is an important aspect. Biorelevant media 
consider drug solubilization in mixed micelles and therefore mimic much better the 
physiological situation than pure buffer solutions. However, the discussion about best 
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suited media composition is still ongoing (Jantratid et al., 2008). The choice of 
technical parameters like the paddle speed or the transfer pump rate has also been 
debated (Kostewicz et al., 2004). Especially the transfer pump rate is reasonable to 
vary, since also gastric emptying is subject to variation. 
Precipitation is a complex process, involving two different mechanisms. It starts with 
nucleation from a supersaturated solution followed by growth of the resulting 
particles. Furthermore processes such as Ostwald ripening or aggregation can occur 
(Kirwan and Orella, 2002; Lindfors et al., 2008). Such aspects of drug precipitation 
were studied earlier, but mainly in the framework of drug substance crystallization in 
chemical synthesis (Shekunov and York, 2000). Here, the LaMer diagram was used as 
a first approach to predict substance precipitation by focusing on the solubilized 
amount of drug (Lamer and Dinegar, 1950). In the meantime the understanding of 
compound supersaturation has evolved and a review article was recently focusing on 
pharmaceutical systems (Brouwers et al., 2009). Herein, the activation energy for 
nucleation ∆G* was described as the driving force of the nucleation process. In the 
simple case of homogenous nucleation, assuming spherical clusters, it can be 
calculated using the following equation: 
  
∆G* = 16pi ⋅ VM
2γ ns3
3(kbT ln(S))2
                                                                                                 (5.1) 
Where VM holds for the molecular volume of the precipitating compound and γns is 
the interfacial energy per unit area between the cluster and the surrounding solvent. 
The equation further includes the Boltzmann’s constant kb and the degree of 
supersaturation S. The latter parameter is simply the ratio of the solute concentration 
in the supersaturated state divided by the equilibrium solubility. This is an important 
equation for ∆G*, which displays the key parameters for the nucleation process under 
69 EXPERIMENTAL SECTION 
 
 
ideal conditions. It must be noted, however, that the presence of polymers or other 
colloids can change precipitation behavior. Apart from the described ideal case, a 
heterogeneous precipitation has been described in the literature (Lindfors et al., 2008). 
This increased level of complexity is one reason for the still limited understanding of 
the precipitation processes in vivo. Such lack of understanding exists also in the area 
of modern in vitro precipitation testing. Only recently, Sugano pioneered in using a 
nucleation and growth model in biopharmaceutical testing (Sugano, 2009). The 
simulated concentrations, however, could not in all cases adequately predict the 
experimental concentration-time profiles. As a consequence, there are still open 
questions with respect to parameters influencing the precipitation mechanisms, 
starting from the composition of the biorelevant media to the transfer rate of the 
simulated gastric fluid into the simulated intestinal fluid. Moreover, there is a need for 
novel analytical tools to monitor the morphology and number of precipitated particles, 
as well as for the study of subsequent processes like aggregation. 
The aim of the present study was to introduce new analytical tools for real-time 
monitoring in a biopharmaceutical transfer test. Drug precipitation was monitored by 
online dynamic image analysis and inline disperse Raman spectroscopy. Moreover, a 
power law modeling approach (Vauck and Mueller, 1994) was adapted for the first 
time to a biopharmaceutical transfer test. We proposed a kinetic nucleation and 
growth model that also considered the pump rate used in the test. As model compound 
dipyridamole was selected. It is a weakly basic BCS II drug, pKa = 6.4 
(www.roempp.com), which is known for its pH-dependent solubility (Kostewicz et 
al., 2004; Russell et al., 1994; Zhou et al., 2005). 
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5.2 Materials and Methods 
5.2.1 Materials 
Dipyridamole, ammonium acetate, diethylamine, maleic acid, sodium chloride, 
sodium hydroxide, and sodium oleate were purchased from Sigma-Aldrich GmbH, 
Switzerland. Pepsin was obtained from Hänseler AG, Switzerland, sodium 
taurocholate was purchased from Prodotti Chimici e Alimentari S.p.A., Italy, and 
glycerol monooleate was supplied from Danisco, Denmark. Finally, 
phopsphatidylcholine was obtained from Lipoid GmbH, Germany. 
5.2.2 Methods 
5.2.2.1 Preparation of simulated gastro-intestinal fluids 
FaSSGF and Fed State Simulated Intestinal Fluid V2 (FeSSIF V2) were used as 
biorelevant media. They were prepared as previously reported using the compositions 
described in Table 5-1 (Jantratid et al., 2008). 
 FaSSGF FeSSIF V2 
Sodium taurocholate (mM) 8*10-2 10 
Lecithin (mM) 2*10-2 2 
Glycerol monooleate (mM) - 5 
Sodium oleate (mM) - 0.8 
Maleic acid (mM) - 55.02 
Sodium chloride (mM) 34.2 125.5 
Sodium hydroxide (mM) - 69.9 
Pepsin (µM) 1.24 - 
pH 1.6 5.8 
FaSSGF: Fasted State Simulated Gastric Fluid, FeSSIF V2: Fed State Simulated Intestinal Fluid 
Table 5-1: Compositions of biorelevant media 
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5.2.2.2 In vitro drug precipitation transfer test 
The in vitro transfer test was conducted using an USP II apparatus (DT 600, 
ERWEKA GmbH, Germany) and dipyridamole was solubilized in 250 ml FaSSGF to 
reach a drug concentration of 3 mg/ml. This solution was pumped into 500 ml 
FeSSIF V2 at transfer rates of 4 ml/min and 9 ml/min using a peristaltic pump (Petro 
Gas Ausrüstungen GmbH, Germany). The media were temperated at 37 ± 0.5°C and 
stirred with a paddle speed of 100 rpm. Samples (n = 3) of 1 ml were each taken at the 
different time points, followed by a filtration through a regenerated cellulose 
membrane, with a pore size of 0.45 µm (SUN-SRi, United States). The samples were 
then instantly diluted with 1 ml medium and visually checked that no drug 
precipitation occurred in further analysis. Subsequently, the concentration of 
dissolved dipyridamole was determined by HPLC. The sample volume taken from the 
acceptor medium was replaced at each time point with fresh temperature adjusted 
FeSSIF V2 medium and the entire transfer test was conducted over 3 h. For a 
visualization of the experimental setup, Figure 5-1 depicts the biopharmaceutical 
transfer test together with the analytical monitoring tools. 
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Figure 5-1: Scheme of the transfer test including the inline Raman spectrometer and the dynamic 
image analysis system as particle analyzer 
5.2.2.3 HPLC assay 
HPLC measurements were performed on a LiChrospher®60, RP select B 125-
4 (5 µm) column (Merck KGaA, Germany). The mobile phase consisted of 
0.5% aqueous ammonium acetate solution, 0.2% methanolic diethylene amine 
solution, and acetonitrile (30:55:15 v/v). Samples of 5 µl were injected and analyzed 
at a flow rate of 1 ml/min and a detection wavelength of 294 nm (Lunn and 
Schmuff, 1997-2000). 
A new calibration line in the range between 0.089 mg/ml and 1.426 mg/ml was 
determined for each series of measurements. All calibration lines were in a linear 
concentration range and exhibited a R2 of higher than 0.999. The limit of detection 
was 0.053 ± 0.000 mg/ml (n = 4) of dipyridamole concentration. 
5.2.2.4 Dynamic image analysis 
Online dynamic image analysis was performed on an XPT-C Particle Analyser (PS 
Prozesstechnik GmbH, Switzerland). Using a peristaltic pump (Ismatec SA, 
Switzerland), the acceptor medium was transported through a measuring cell, 
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equipped with a Flea 2, 1392 x 1032 pixel CCD-camera to analyze the formation of 
particles/aggregates. The camera performed 70 measurements in a minute, whose 
average was reported. Data on number, shape and size of the particles or aggregates, 
respectively were gathered. The number of particles was counted in a total volume of 
153 mm3 and subsequently used to calculate the corresponding particle 
concentrations. The particle sizes were evaluated as Waddle Disk Diameter (WDD), 
representing the diameter of a disk with an equal area to the projected area (A) of the 
observed particle/aggregate: 
  
WDD = 2 A
p
                                                                                                           (5.2) 
5.2.2.5 Raman spectroscopy 
The in vitro transfer test was monitored in the acceptor phase using a dispersive 
Raman spectrometer RamanRXN1 Systems (Kaiser Optical Systems, Inc., United 
States) equipped with a CCD-camera and a fibre optic probe (spot size 0.007 mm2). A 
diode laser emitting at 785 nm with a power of 400 mW was used. An exposure time 
of 20 s every 3 min was chosen to record a spectrum in the range of 
100 cm−1 to 3425 cm−1, while averaging every spectrum over 5 scans. To avoid the 
influence of light on the measurements, the dissolution vessel was completely 
wrapped in aluminium foil. 
5.2.2.6 Mathematical modeling and statistical analysis 
We developed a mathematical model that was based on a power law for describing the 
kinetics of nuclei formation and growth (Vauck and Mueller, 1994). This model took 
into account the transfer of simulated gastric to intestinal fluid at a set rate. The 
resulting equations were fitted to the experimental concentration data using EASY-
FIT software (K. Schittkowski, University of Bayreuth, Germany). The algorithm of 
this program was modeling the sum of squared residuals. However, since it was not 
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possible to estimate all parameters simultaneously, a two-step procedure was applied. 
Fitting was performed with fixed exponent values set between a range of 2 to 9 for the 
nucleation exponent and we tested values of 1 to 2 for the growth exponent in line 
with the reported literature span (Vauck and Mueller, 1994). Each fitting with a given 
exponent provided residuals for calculating the root mean square error (RMSE). This 
value was subsequently modeled using STATGRAPHICS Centurion, Inc., United 
States, to find the best exponent combination for each flow rate separately. 
For the statistical treatment of the Raman data, all spectra were corrected for the 
baseline. A wavelength range from 504 cm-1 to 2922 cm-1 was selected for a 
multivariate analysis of Raman intensities. Accordingly, the response of the model 
was the precipitated drug as obtained from the HPLC data. The calculations were 
performed using the software IC Quant™ Module 1.0 (Mettler Toledo International, 
Inc., Switzerland) to propose an optimal partial least square (PLS) model. This model 
exhibited on the one hand a minimal root mean square error of calibration (RMSEC), 
while on the other hand the predicted residual sum of squares was minimal as well. 
Finally, the standard errors (SE) in the figures and tables were calculated using 
Excel V.2003 (Microsoft Corp., United States). 
5.3 Results 
5.3.1 Solubilities of the model drug dipyridamole 
The measured equilibrium solubility of dipyridamole at 37 ± 0.5°C in FaSSGF was 
17.2 ± 0.5 mg/ml and 0.068 ± 0.009 mg/ml in FeSSIF V2. The solubility sharply 
decreased with increasing pH in line with expectation. This resulted in a low 
dipyridamole solubility of 0.017 ± 0.004 mg/ml, in the final medium mixture at the 
end of the transfer experiment (FaSSGF : FeSSIF V2 = 1 : 2, pH 5.4), which was 
reasonably close to the value in pure FeSSIF V2. 
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5.3.2 Dynamic image analysis of the in vitro drug precipitation 
transfer test 
The dynamic image analysis revealed that following a lag time, the drug precipitated 
as complex particles. As shown in Figure 5-2, these particles were either star-like 
crystals or they were formed through an instantaneous aggregation of elongated 
primary particles. Both flow rates 4 ml/min and 9 ml/min led to the same habit of the 
forming particles. We confirmed this form of the particles/aggregates by directly 
taking samples for light-microscopic analysis. Accordingly, the results were not 
apparently influenced by the pumping of medium into the camera system of the 
dynamic image analysis. 
2.29 mm
1.
67
 
m
m
 
Figure 5-2: Dipyridamole–precipitates after 3 h in the acceptor phase at 37°C, flow rate 9 ml/min, 
resulting picture of the XPT-C Particle Analyser, including an enlarged image captured with a 
microscope 
Figure 5-3 depicts the time dependent sequence of the particle/aggregate 
concentration in the acceptor phase. For the high flow rate of 9 ml/min, a lag time 
of ≅ 10 min and a maximum number of particles/aggregates was observed following 
20 min. The lower transfer rate on the other hand showed a longer lag time of about 
20 min, which was explained by the slower increase in concentration in the acceptor 
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phase compared to the higher transfer rate. A maximum particle/aggregate number 
was seen following approximately 30 min. The subsequent decrease in particle counts 
was probably the result of further particle aggregation and redissolution of a small 
particle fraction. Finally after one hour, the particle concentrations almost reached an 
equilibrium showing no differences between the flow rates any more. 
 
Figure 5-3: Particles/aggregates concentrations of dipyridamole (mean ± SE) 
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Figure 5-4: Size distribution at flow rate 4 ml/min (mean ± SE) 
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Figure 5-4 (flow rate 4 ml/min) and Figure 5-5 (flow rate 9 ml/min) show the 
particle/aggregate size distributions for different time points. Interestingly, not only 
the mean size, but also the width of the distribution changed over time. Thus, the peak 
of the size distributions shifted towards larger particle sizes over time. The obtained 
size distributions were comparatively broad and did not change from 60 min to 
180 min. Furthermore, the width of the particle aggregate distribution depended on 
the transfer rate. 
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Figure 5-5: Size distribution at flow rate 9 ml/min (mean ± SE) 
In a next step, the results of the dynamic image analysis were compared with the 
concentrations of solubilized dipyridamole in the acceptor phase (Figure 5-6). The 
concentrations did not increase in a strictly cumulative manner. Decreasing values 
were observed once a marked crushing out of drug occurred. At the higher flow rate, 
the peak concentration was reached after 15 min with a value of 0.65 ± 0.05 mg/ml.
 
In 
contrast the lower flow rate of 4 ml/min, exhibited the maximum concentration of 
0.47 ± 0.03 mg/ml after 25 min. 
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Figure 5-6: Profile of solubilized dipyridamole at flow rate 4 ml/min and 9 ml/min (mean ± SE) 
5.3.3 Raman spectroscopy 
Raman spectra were inline recorded as a function of time. Figure 5-7 shows the 
results of a selected wavelength range at the rate of 9 ml/min. Herein the changes of 
the 1350 cm-1 to 1400 cm-1 signal were of particular interest. Data recording started 
40 min prior to the transfer test returning only a small signal at the beginning of the 
experiment. The significant increase in the signal over the course of the transfer test 
correlated well with the amount of precipitated drug that was obtained from the HPLC 
data. Such change of Raman intensities over time was considered as an indicator for 
the onset of drug precipitation. At flow rate of 9 ml/min we observed the onset of 
nucleation after 13 min and at the flow rate of 4 ml/min after 23 min. 
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Figure 5-7: 3D plot of a Raman spectrum in the range of 1315 cm-1 to 1505 cm-1, flow rate 9 ml/min 
To correlate the Raman intensities with the amounts of precipitated drug, we 
considered a broader range of the Raman spectrum from 504 cm-1 to 2922 cm-1. A 
PLS model was found with four principal components resulting in an R2 value of 
0.995 and the calibration line is depicted in Figure 5-8 using data at the transfer rate 
of 9 ml/min. The model showed that Raman monitoring provided a sensitive tool for 
detecting drug precipitation in the acceptor vessel. 
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Figure 5-8: Calibration line of the Raman PLS model with the precipitated drug as response variable 
5.3.4 Mathematic modeling 
It is generally known that precipitation is a two-step process composed of nucleation 
and particle growth (Kirwan and Orella, 2002). For this reason our model assumptions 
started with established kinetic crystallisation equations (Vauck and Mueller, 1994). 
At time t = 0 the solubilized amount of drug Msol as well as the precipitated amount 
Mpr are 0. Ci is the effectively solubilized concentration of dipyridamole in the 
acceptor medium at time point t throughout the entire process and is described by 
  
c i =
Msol
Vi
                                                                                                                  (5.3) 
We divided the entire transfer and precipitation kinetics into four time intervals: 
I. From the beginning to the start of nucleation: [0, tnu] 
II. From the start of nucleation to the end of the medium transfer: [tnu, ttr] 
III. From the end of the medium transfer to the start of particle growth: [ttr, tgr] 
IV. From the beginning of particle growth to infinity: [tgr, ∞] 
The following equations apply to each time interval: 
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Interval I [0, tnu]: 
  
dMsol
dt
= Ftr ⋅ cg                                                                                                 (5.4) 
  
dMpr
dt
=0                                                                                                        (5.5) 
Vi = Vi0 + Ftr · t                                                                                              (5.6) 
 
Where Ftr describes the transfer rate used to pump FaSSGF, containing the 
solubilized drug, into the FeSSIF. The parameter cg represents the 
concentration of dissolved dipyridamole in FaSSGF (3 mg/ml). 
 
Interval II [tnu, ttr]: 
  
dMsol
dt
= Ftr ⋅ cg  - knu (ci – csat)n                                                                        (5.7) 
  
dMpr
dt
=knu (ci – csat)n                                                                                     (5.8) 
Vi = Vi0 + Ftr · t                                                                                              (5.6) 
Vi0 in the equation represents the initial volume of 500 ml at t = 0, whereas Vi 
stands for the volume at any time point t. The coefficient knu describes the 
nucleation constant, csat (0.017 mg/ml) the saturation concentration, and n 
represents the nucleation exponent. 
 
Interval III [ttr, tgr]: 
  
dMsol
dt
=- knu (ci – csat)n                                                                                  (5.9) 
  
dMpr
dt
=knu (ci – csat)n                                                                                     (5.8) 
Vi = Vi0 + Ftr · ttr                                                                                           (5.10) 
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Interval IV [tgr, ∞]: 
  
dMsol
dt
=- kgr (ci – csat)g                                                                                (5.11) 
  
dMpr
dt
=kgr (ci – csat)g                                                                                   (5.12) 
Vi = Vi0 + Ftr · ttr                                                                                           (5.10) 
 
Where kgr is the particle growth constant and g the corresponding particle 
growth exponent. 
 
The aforementioned set of equations was fitted to the individual concentration 
profiles. Interestingly, the fits for the different flow rates revealed the same optimum 
with respect to their exponents. We found 5 for the nucleation exponent and 1.5 for 
the growth exponent. This consistent finding indicated that the different flow rates 
obviously produced the same kind of drug precipitation process. 
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Figure 5-9: Example of dipyridamole concentration profiles (points) together with the mathematical 
model (solid line) for the flow rate of 4 ml/min 
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Figure 5-10: Example of dipyridamole concentration profiles (points) together with the mathematical 
model (solid line) for the flow rate of 9 ml/min 
Examples of both flow rates are shown in Figure 5-9 and Figure 5-10. The model 
excellently agreed with the measured concentration profile over time. Interestingly, 
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the profiles displayed a shoulder that followed the main peak. This shoulder marked 
the end of medium transfer into the simulated intestinal acceptor fluid. It was 
remarkable that the mathematical model was able to agree on this rather subtle effect 
of the concentration profile. The individual fitting curves resulted in parameter 
estimates that were averaged as displayed in Table 5-2. 
 4 ml/min 9 ml/min 
n 5 5 
gr 1.5 1.5 
knu 11645.69 ± 385.53 6765.74 ± 2135.50 
kgr 7.47 ± 0.46 8.46 ± 0.29 
tnu 28.06 ± 0.88 min 18.52 ± 0.91 min 
tgr 68.01 ± 1.36 min 52.89 ± 17.96 min 
n: nucleation exponent, gr: particle growth exponent, knu: nucleation constant, kgr: particle growth constant, 
tnu: start time of nucleation, tgr: start time of particle growth 
Table 5-2: Estimated values of the fitted kinetic nucleation and growth model for the two transfer rates 
(mean ± SE) 
5.4 Discussion 
The in vitro testing was performed using FaSSGF as acidic medium to simulate the 
gastric environment, whereas the acceptor medium was not only chosen based on the 
most updated biorelevant media composition, but also for technical reasons. Thus, 
pure FeSSIF V2 showed the lower background signal in the XPT-C Particle Analyser 
compared to FaSSIF V2, making it better suited to study in vitro drug precipitation. 
The combination of FaSSGF and FeSSIF V2 was therefore selected to study in vitro 
the change in pH, triggered by the transfer from the stomach to the intestine. The 
media selection had the advantage of a large pH change, but it was on the other hand 
not possible to study an effect of the fasting versus fed state condition. 
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Another factor that needed consideration during the in vitro test, was the paddle 
speed. Previous experiments interestingly showed that this parameter had only a 
minor effect on the measured profiles in the acceptor phase (Kostewicz et al., 2004). 
For this reason an arbitrary constant paddle speed of 100 rpm was selected for all 
experiments. The more important parameter for the in vitro test, however, was the 
transfer rate. It was not only relevant for the in vitro results, but is also important for 
the in vivo situation (Kostewicz et al., 2004). As the gastric emptying defines when a 
dissolved drug in the stomach is transferred to the intestinal fluid, we used different 
flow rates in vitro that were considered to be relevant for physiological gastric 
emptying (Kostewicz et al., 2004). 
Using dynamic image analysis it was demonstrated that the transfer rate was affecting 
the precipitation kinetics. A common aspect of the investigated transfer rates was that 
similar complex particles/aggregates were obtained. The mean particle size and size 
distribution as well as the concentration profile showed a clear dependence on the 
transfer rate. Based on particle number and size, the dynamic image analysis agreed 
with the observed decreasing drug concentration due to precipitation in both cases. 
Care is however needed, when comparing the size and concentration data on a 
quantitative basis, since the density of the particles/aggregates is unlikely to stay 
constant over time. For this reason we did not include the dynamic image analysis 
data for modeling of the concentration profiles. 
The faster transfer rate provided the higher drug concentration peak in the intestinal 
medium. It could therefore be hypothesized that under such conditions, also the 
absorption process is promoted in vivo. However, our transfer test did not consider 
any drug absorption. Unlike the in vivo situation, no permeation step was involved in 
vitro so that no continuous removal of drug from the bulk solution could be taken into 
EXPERIMENTAL SECTION 86 
 
 
account. More research is therefore needed to clarify the biorelevance of the current in 
vitro transfer test. 
However, on the level of the in vitro test itself, the new monitoring tools provided 
insights into the process of in vitro drug precipitation. Disperse Raman spectroscopy 
hereby showed to be particularly useful. It enabled the definition of precipitation 
onset and following the amount of precipitated drug. The latter was in good 
agreement with the concentration data gathered by HPLC analysis. Raman 
spectroscopy appears to be a valuable tool for the monitoring of biopharmaceutical 
tests, which was recently also highlighted in another publication (Savolainen et 
al., 2009). This work studied the in situ solid state of indomethacin and carbamazepin 
in a flow-through dissolution test. The authors were able to follow changes from the 
amorphous drug to the crystalline state during the dissolution process. Such changes 
in the solid-state properties can be of biopharmaceutical relevance and possibly 
depend on the dissolution medium used. Especially the biorelevant media can hereby 
influence a solvent-mediated solid-phase transformation (Letho et al., 2009). 
For the transfer test it is of interest to see if the drug undergoes changes in solid-state 
structure during the precipitation process. Even though a drug can potentially 
precipitate in an amorphous form or as a hydrate, the Raman spectrum of the 
precipitated model compound dipyridamole revealed no differences compared to its 
initial crystalline form. 
Next to gaining a better understanding of in vitro drug precipitation kinetics by using 
analytical monitoring tools, mathematical modeling also provided valuable insights. 
We used power laws to model nucleation as well as the growth of the particles. Based 
on minimum RMSE values, the best models had the same exponents for both transfer 
rates. The nucleation exponent of 5, delivered by the model, was well within the 
87 EXPERIMENTAL SECTION 
 
 
expected range of 3 to 6 (Vauck and Mueller, 1994). It should be modeling that the 
formation of drug nuclei and the concentration differences in solution showed a 
highly non-linear relationship. The particle growth exponent, returned by the model, 
was 1.5. It is interesting to note that this growth exponent was found to be greater 
than 1. A simple approximation for particle growth would be a first order “inverse 
dissolution process” according to Noyes Whitney, resulting in a particle growth 
exponent of 1. Such type of particle growth was previously applied (Sugano, 2009). 
However, exponents higher than 1, as observed in our experiments, were also inline 
with previous experimental findings (Vauck and Mueller, 1994). They probably 
originate from geometric effects, as complex structures of particles and surfaces can 
be the result of a precipitation/aggregation process (Lin et al., 1989), resulting in 
deviation from a simple first order model (Macheras and Iliadis, 2002; Valsami and 
Macheras, 1995). Accordingly, our growth exponent of 1.5 rather that 1 can be the 
result of a complex particle surface, which defines the true surface area being 
available for drug dissolution and/or precipitation. This assumption of a complex 
surface agreed well with the images obtained from online monitoring that 
demonstrated a complex geometry of the precipitated particles/aggregates. It would be 
interesting to learn from future tests, how the exponents depend on surface properties 
of other precipitated drugs than dipyridamole. 
The mathematical model was also of a particular interest in the determination of the 
nucleation onset. This time point is difficult to assess by experimental means, since 
the initial nuclei are expected to be subvisible as well as instable. Accordingly, the 
image analysis can only detect particles in a size range of a few micrometers and also 
Raman spectroscopy has a limited resolution with respect to detecting a small fraction 
of crystalline drug. Given these limitations, it is remarkable that the calculated 
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nucleation time (Table 5-2) agreed well with the precipitation onset determined by 
Raman spectroscopy as well as obtained from dynamic image analysis. 
The novel tools, i.e. inline Raman spectroscopy and online dynamic image analysis, 
as well as HPLC data provided a coherent view on the precipitation process. The in 
vitro tools allowed a suitable monitoring of the process and the mathematic model 
facilitated an improved understanding of the in vitro drug precipitation. The obtained 
model coefficients are expected to be specific for a pharmaceutical compound in a 
given medium. Determination of these coefficients is of special interest with respect 
to mechanistic drug absorption modeling. These parameters can be used as input data 
for physiologically-based pharmacokinetic (PBPK) models. Such mechanistic 
modeling is today available from a few commercial software packages. However, the 
mathematical models presently do not consider the precipitation process in its full 
complexity, i.e. through consideration of a separate nucleation and growth step. 
Consequently, the PBPK models need to be refined in that respect and our calculated 
coefficients could then serve as input parameters to obtain mechanistically improved 
simulations for drug absorption. 
5.5 Conclusions  
Using a biorelevant transfer test, we examined precipitation of dipyridamole in vitro. 
Novel analytical methods were introduced together with a mathematical model for 
nucleation and particle growth. The dynamic image analysis revealed a complex 
structure of the precipitated particles/aggregates, which was also reflected in the 
mathematical model by a growth exponent differing from 1. The particle size 
distribution changed as a function of time and differences between the transfer rates 
were mainly observed in the initial phase of the precipitation. These observations also 
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agreed with the findings of the inline Raman spectroscopy that demonstrated to be an 
excellent tool in monitoring the precipitated drug fraction. 
It can be concluded that a simple measurement of drug concentration in the acceptor 
phase does not provide a complete characterization of in vitro drug precipitation. The 
underlying processes are highly complex especially in biorelevant media, so that 
further analytical tools are required. The combined efforts of modeling and advanced 
analytical monitoring provide important insights into drug nucleation and particle 
growth. Furthermore these results can be used for a subsequent mechanistic 
absorption modeling. Physiologically based absorption modeling can facilitate 
correlations with in vivo findings. Accordingly, we must have a good understanding 
of the in vitro results to enable meaningful in vivo correlations. This is also the key to 
better optimizing the in vivo performance of pharmaceutical formulations based on in 
vitro results. 
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6 STUDY OF DRUG CONCENTRATION EFFECTS ON 
IN VITRO LIPOLYSIS KINETICS IN MEDIUM-
CHAIN TRIGLYCERIDES BY CONSIDERING OIL 
VISCOSITY AND SURFACE TENSION 
6.1 Introduction 
Lipolysis in the intestine is a complex process in which pancreatic lipase is mainly 
responsible for digestion of triglycerides. The enzyme acts on the oil/water interface, 
where it exhibits a rather weak adhesion. Therefore substances like proteins or bile 
salts can easily remove the lipase from the interface and block any further digestion 
(Embleton and Pouton, 1997). To avoid desorption of the enzyme from the oil/water 
interface, lipase interacts with the colipase to form a strongly adhering complex. 
Anchored at the interface, pancreatic lipase catalyzes the hydrolysis of tri- as well as 
diglycerides resulting in fatty acids and 2-monoglycerides. The latter can undergo a 
non-enzymatic isomerization to 1-monoglyceride that is digestible by the pancreatic 
lipase to form glycerol and fatty acid (Embleton and Pouton, 1997). 
It was early recognized that surface-active excipients can greatly affect the lipolysis 
rate (Hutchison, 1994). Some of these lipid-based surfactants were shown to be 
digested themselves (Fernandez et al., 2007; Fernandez et al., 2008). Moreover a 
study of Cuiné et al. reported formulations with high amounts of digestible surfactant, 
which were leading to drug precipitation (Cuiné et al., 2008). Based on these in vitro 
results, a formulation ranking was determined that was later observed in beagle dogs.  
The field of in vitro lipolysis still offers many opportunities for pharmaceutical 
research and our work focused on a potential drug loading effect. Earlier studies 
investigated poorly soluble compounds at a single concentration (Christensen et 
al., 2004; Kaukonen et al., 2004). A next step would be to study drug concentration 
effects, which to the best of our knowledge has not been explored. We aimed studying 
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the influence of five poorly soluble model drugs on the in vitro lipolysis rate in 
medium-chain triglycerides (type I formulation) using three concentration levels. The 
drug orlistat was furthermore analyzed as reference, due to its known selective direct 
inhibition of the pancreatic lipase (Hadvàry et al., 1988; Hauptmann et al., 1992). In 
order to achieve a better mechanistic understanding of drug effects on lipolysis, direct 
compound effects on physical oil properties were studied. All compounds were first 
characterized by molecular modeling followed by studying drug effects on oil 
viscosity and surface tension. In theory, these physical parameters were of relevance 
for any kind of oil dispersing or surface reaction and therefore of interest for lipolysis 
testing. 
6.2 Materials and methods 
6.2.1 Materials 
The chemicals danazol, calcium chloride dihydrate, fenofibrate, griseofulvin, maleic 
acid, porcine pancreatin, probucol, sodium chloride, sodium hydroxide, and 0.2 N 
sodium hydroxide were purchased from Sigma-Aldrich GmbH, Switzerland. 
Miglyol®812 was obtained from Hänseler AG, Switzerland. This medium-chain oil 
comprised triglycerides of 50% to 65% caprylic acid (C8:0) and 30% to 45% of capric 
acid (C10:0). A maximal amount of 2% was specified for caproic acid (C6:0) as well as 
for lauric acid (C12:0). Finally, the content of myristic acid (C14:0) was maximally 1%. 
Sodium taurocholate (purity > 99% w/w) was purchased from Prodotti Chimici e 
Alimentari S.p.A., Italy, lecithin (grade EPCS > 98% phospholipids) was obtained 
from Lipoid GmbH, Germany, and felodipine was supplied by Ramidus AB, Sweden. 
Finally, orlistat was obtained from AK Scientific, Inc., United States. 
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6.2.2 Methods 
6.2.2.1 Preparation of drug formulations 
The different drugs and the medium-chain triglyceride oil were mixed in glass vials 
using a constant stirring. We targeted a broad concentration range for each drug to 
assure that transparent oily solutions were obtained. This individual range was then 
used to define three arbitrary concentrations for each drug. Concentration levels were 
named as “low”, “intermediate”, and “high” (Table 6-1) and all samples were visually 
checked for clarity during 7 days to assure that no drug precipitation occurred. 
 
Drug concentration in MCT 
(mg/ml) 
 Low Intermediate High 
Danazol 0.31 0.55 1.31 
Felodipine 0.19 1.35 2.90 
Fenofibrate 2.75 28.50 50.40 
Griseofulvin 0.25 0.49 0.74 
Probucol 0.69 1.67 5.29 
Orlistat 5.00 10.00 20.00 
Table 6-1: Drug concentration levels in MCT 
6.2.2.2 Molecular modeling 
Different molecular parameters were calculated using the program Molecular 
Modeling Pro, Version 6.2.6 (ChemSW, Inc., United States). The number of proton 
donors was determined first together with a three dimensional solubility parameter. 
The latter value employed the definition by Van Krevelen (1997). HLB values were 
obtained according to Griffin’s definition based on molecular weight. This measure of 
the molecule’s amphiphilic character was complemented with the calculation of the 
critical packing parameter. The latter estimate was determined by the hydrophobic 
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molecule volume divided by two parameters. One was a slice area through the 
hydrophilic head group of the molecule and the other was the longest length of the 
hydrophobic part of the structure. Since most of the octanol/water coefficients log P 
were experimentally known, we used the values of the drug bank (www.drugbank.ca) 
to have a physicochemical reference value. 
6.2.2.3 Capillary viscosimetry 
Viscosity was measured according to the Ubbelohde capillary method. Thus, a Schott 
capillary viscosimeter of size II (SI Analytics GmbH, Germany) was held at constant 
temperature of 37°C. This capillary was filled with formulation to a given meniscus 
height. Following temperature equilibration, time was determined for the sample to 
flow between defined meniscus levels. Subsequently, the kinematic viscosity was 
calculated by taking the capillary constant into consideration. The obtained viscosity 
value was corresponding to the dynamic viscosity normalized by the density. All 
concentrations in Table 6-1 were tested in triplicate. 
6.2.2.4 Dynamic surface tensiometry 
Surface tensions at room temperature were measured using the Sita DynoTester 
(SITA Messtechnik GmbH, Germany). The measurement principle is based on the 
bubble pressure method. Air was introduced through an orifice into the liquid samples 
so that a succession of bubbles was generated. Herein an arbitrary range of 
frequencies was tested, which provided different surface ages of 25 ms, 250 ms, and 
2500 ms. During inflation of a bubble, the pressure increases from base value p0 to a 
maximal bubble pressure pmax. At the latter, the bubble radius equaled to that of the 
capillary r. The dynamic surface tension σd was then calculated according to the 
following equation 6.1: 
  
σd =
(pmax − p0)r
2                                                                                                (6.1) 
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All the measurements were taken in triplicate. 
6.2.2.5 Dynamic lipolysis test 
The enzymatic test was performed in the biorelevant medium FaSSIF having a 
composition that was recently updated to a version 2 (Jantratid et al., 2008). This 
medium contained 3 mM of sodium taurocholate, 0.2 mM lecithin, 19.12 mM maleic 
acid, 68.62 mM sodium chloride, and 34.8 mM sodium hydroxide. The pH of this 
medium was adjusted to 6.5. 
The porcine pancreatin was suspended in this biorelevant medium (0.174 mg 
pancreatin/ml medium). After stirring the dispersion at room temperature (15 min, 
25 ± 0.5°C), the dispersion was centrifuged using an Eppendorf Centrifuge 5415C 
(Vaudaux-Eppendorf AG, Switzerland) for 15 min at 14000 rpm. The clear 
supernatant was collected and adjusted to pH 6.5. The resulting solution exhibited an 
enzyme activity of 10000 TBU per ml. The solution was freshly prepared each day. 
Sample (500 µl) was dispersed in 36 ml medium at 37°C in a double-walled glass 
vessel. The solution was equilibrated for 15 min using magnetic stirring. 
Subsequently, lipolysis was started by adding 4 ml pancreatin solution (1000 TBU/ml 
final concentration) and 5 mM calcium chloride dihydrate. Lipolysis products were 
then titrated with 0.2 NaOH using a computer controlled Titrando 842 (Metrohm 
Schweiz AG, Switzerland). 
6.2.2.6 Statistical design and analysis of data 
All measurements were conducted with n = 3 and results were expressed as mean 
values ± standard deviations. The program Statgraphics Centurion XV ed. 
Professional from StatPoint Technologies, Inc., United States, was used for the two-
factor ANOVA calculations. For the subsequent contrast analysis, Fisher’s least 
significant difference (LSD) procedure was followed. LSDs were intervals for each 
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pair of means at the 95% confidence level using Student’s t distribution. Significance 
was assumed for those factors that demonstrated a probability p-value of less than 
0.05. 
6.3 Results 
6.3.1 Physicochemical drug effects in oils 
6.3.1.1 Modeling of molecular parameters with potential relevance for drug 
effects on the oil 
The different drugs were characterized by means of molecular modeling. Only 
selected molecular properties were calculated that were of interest with respect to 
drug/oil interactions (Table 6-2). Thus, a first molecular parameter was the number of 
proton donors. Such protons were earlier shown to be relevant for the interaction with 
ester groups in oils (Cao et al., 2004). In that respect, danazol, felodipine, probucol, 
and orlistat could facilitate hydrogen bonding. Apart from the number of proton 
donors, the solubility parameter was calculated. This estimate of the cohesive energy 
was in case of orlistat remarkably low. 
 
Number 
of proton 
donors 
Solubility 
parameter 
(J/cm3)0.5 
 
HLB, 
 based on 
molecular 
weight 
 
 
Critical 
packing 
parameter 
 
 
 
log P 
Danazol 1 23.54 3.12 0.38 0.51* 
Felodipine 1 23.52 4.82 0.99 3.8* 
Fenofibrate 0 22.67 2.55 0.44 5.3* 
Griseofulvin 0 24.49 5.89 0.66 2* 
Probucol 2 22.79 0.49 0.5 7.03 
Orlistat 1 18.37 4.15 0.31 8.92* 
*The known experimental log P values were listed according to the drug bank (www.drugbank.ca) 
Table 6-2: Compound properties obtained from molecular modeling 
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The balance of the hydrophilic and lipophilic part of a molecule was estimated by the 
calculated HLB value. As a result, the compounds differed with respect to their 
amphiphilic nature. Comparatively high HLB values were calculated for griseofulvin, 
felodipine, and orlistat. These compounds had the highest potential of surface activity 
by migrating to the oil surface or the oil/water interface. However, all calculations 
were based on assumed molecular conformations. Changes in these molecular 
conformations affect the calculated HLB values so that the estimate is not absolute 
but depends on the drug environment. Such dependence on the molecular 
conformation was further given with the calculation of the critical packing parameter. 
This value described the ratio of polar head group volume to the volume of the 
lipophilic moiety in the amphiphilic molecule. High values among the test compounds 
were mainly obtained for felodipine and griseofulvin. The model assumed that these 
compounds exhibit the tendency to aggregate in planar structures. 
6.3.1.2 Drug effects on viscosity and surface tension of the oil 
The focus on viscosity had the rational that there is a theoretical relation with 
molecular diffusion and therefore the potential to interact with oil dispersion or with 
interfacial catalysis. We measured this parameter by means of capillary viscosimetry. 
Table 6-3 displays the results for the different drug concentrations. 
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Kinematic viscosity ± std. (mm2/s) of different drug 
concentrations in MCT 
(value of pure oil: 25.1 ± 0.1) 
 Low Intermediate High 
Danazol 25.3 ± 0.1 25.6 ± 0.1 25.6 ± 0.1 
Felodipine 25.4 ± 0.2 24.2 ± 0.1 25.6 ± 0.2 
Fenofibrate 25.6 ± 0.0 26.6 ± 0.1 27.9 ± 0.1 
Griseofulvin 25.5 ± 0.1 25.6 ± 0.1 25.5 ± 0.0 
Probucol 25.4 ± 0.0 25.6 ± 0.0 26.7 ± 0.1 
Orlistat 26.2 ± 0.1 26.3 ± 0.2 26.8 ± 0.1 
Table 6-3: Kinematic viscosity of different drug concentrations in MCT 
Kinematic viscosity of the pure Miglyol®812 was 25.1 ± 0.1 mm2/s. This reference 
viscosity was generally increased in presence of the poorly soluble drugs. A two-
factor ANOVA was conducted with the type of drug as first factor and its 
concentration effect as a second parameter. Both effects were highly significant in this 
study (p < 0.0001, confidence level of 95 %). 
 
Figure 6-1: ANOVA means plot of drugs and their concentration effects on kinematic viscosity 
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Comparing the different drugs (Figure 6-1), viscosity increase was most pronounced 
with fenofibrate and orlistat. Furthermore, probucol increased viscosity of pure oil. 
The drug effect was depending on concentration and it was most evident at the highest 
drug load. Despite the statistical significance of the effect, absolute changes in 
viscosity were rather moderate. 
Apart from viscosity, the dynamic surface tension was measured. This measure of 
surface activity was potentially indicating effects on the specific energy at the 
oil/water interface, where an interaction with lipolysis is possible. Thus, dynamic 
surface tension was measured for different surface ages from 25 ms to 2500 ms. 
Highest surface age produced the best reproducibility and these data were compiled in 
Table 6-4 (data of surface ages 25 ms and 250 ms are shown in the appendix, section 
9.2.1). 
 
Surface tension ± std. (mN/m) of different drug 
concentrations in MCT 
(value of pure oil: 28.5 ± 0.2) 
 Low Intermediate High 
Danazol 28.8 ± 0.1 28.5 ± 0.2 28.6 ± 0.3 
Felodipine 27.0 ± 0.1 27.0 ± 0.1 28.2 ± 0.2 
Fenofibrate 28.8 ± 0.1 28.9 ± 0.1 29.3 ± 0.2 
Griseofulvin 28.4 ± 0.1 28.7 ± 0.1 30.9 ± 0.1 
Probucol 32.4 ± 0.1 29.0 ± 0.2 29.3 ± 0.7 
Orlistat 26.8 ± 0.2 26.8 ± 0.1 26.8 ± 0.0 
*Surface age of 2500 ms 
Table 6-4: Surface tension of different drug concentrations in MCT 
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The presence of drug in the oil obviously altered dynamic surface tension of pure oil. 
Not all compounds affected this value in the same way. A clear reduction in surface 
tension was, for example, noted for the different concentrations of orlistat. Felodipine 
demonstrated a similar tendency toward lowering the surface tension. On the other 
hand the compound probucol increased the average surface tension. 
An ANOVA means plot is given as Figure 6-2. There was a highly significant effect 
between the different groups (p < 0.0001, confidence level of 95 %). Confidence 
bands of felodipine and orlistat supported the first impression that these drugs reduced 
surface tension of medium-chain triglycerides. The opposite effect was found with 
griseofulvin and probucol that reached highest surface tensions. 
 
Figure 6-2: ANOVA means plot of drugs and their concentration effects on surface tension 
6.3.2 Drug effects on in vitro lipolysis kinetics 
Lipolysis testing was conducted at 37°C using biorelevant medium FaSSIF V2 
(Jantratid et al., 2008). Released free fatty acids were titrated with 0.2 N NaOH using 
a computer controlled pH-stat. To identify effects of the biorelevant medium as well 
as of the pure drugs, blank titrations were performed first. Biorelevant medium 
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displayed an almost immediate NaOH consumption of 0.39 ± 0.05 ml that was further 
on kept at a nearly constant level (at 30 min it was 0.40 ± 0.04 ml). Finally we 
verified that the drugs alone in FaSSIF V2 were as was expected from their neutral 
character not leading to relevant NaOH consumption. 
Pure medium-chain triglycerides were then titrated and the results are shown as 
reference in Figures 6-3 to 6-8. We determined the lipolysis up to 3 h, which was 
considered the longest time still physiologically meaningful. The consumed NaOH 
leveled off so that at 3 h the value of 10.86 ± 0.04 ml was reached. The lipolysis 
degree during the test was then calculated with reference to this maximal value. Pure 
oil therefore exhibited a lipolysis degree of 28.31 ± 2.01% following 30 min and 
51.71 ± 6.46% at 1 h. 
 
Figure 6-3: NaOH consumption in ml throughout lipolysis of 0.5 ml Miglyol®812 and 0.5 ml 
Miglyol®812 including three concentrations of danazol 
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Figure 6-4: NaOH consumption in ml throughout lipolysis of 0.5 ml Miglyol®812 and 0.5 ml 
Miglyol®812 including three concentrations of felodipine 
 
 
Figure 6-5: NaOH consumption in ml throughout lipolysis of 0.5 ml Miglyol®812 and 0.5 ml 
Miglyol®812 including three concentrations of fenofibrate 
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Figure 6-6: NaOH consumption in ml throughout lipolysis of 0.5 ml Miglyol®812 and 0.5 ml 
Miglyol®812 including three concentrations of griseofulvin 
 
 
Figure 6-7: NaOH consumption in ml throughout lipolysis of 0.5 ml Miglyol®812 and 0.5 ml 
Miglyol®812 including three concentrations of probucol 
103 EXPERIMENTAL SECTION 
 
 
 
Figure 6-8: NaOH consumption in ml throughout lipolysis of 0.5 ml Miglyol®812 and 0.5 ml 
Miglyol®812 including three concentrations of orlistat 
The results for danazol, felodipine, and fenofibrate are shown in Figure 6-3, Figure 
6-4, and Figure 6-5. The drugs interestingly had a strong influence on in vitro 
lipolysis. The lipolysis extent as well as the rate of the process were clearly lowered. 
Hereby, the different compounds exhibited a similar effect when compared to the pure 
oil. A comparison of the low concentration (squares), intermediate concentration 
(triangles), and high concentration (crosses) did not reveal a clear trend. Thus, no 
marked effect of concentration was observed. 
Instead of relying on absolute values, we opted for calculation of a rate of free fatty 
acids titrated. Initial time points were neglected and the titration rate was found to be 
nearly linear between 10 min and 40 min with R2 values of regression lines higher 
than 0.9. One exception was orlistat, which was expected because of the very small 
slope that was displayed for this potent lipolysis inhibitor. 
We named the rate in the given time interval as “apparent linear lipolysis rate”. It was 
only an apparent value, since apart from assumed linearity, the rate was based on 
further approximation. Titrated NaOH volumes were not exactly corresponding to the 
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released fatty acids, since we cannot assume complete ionization of these lipolysis 
products. The titrated value was therefore only approximating the released fatty acids. 
An advantage of this rate definition was, however, its independence from initial 
NaOH consumption (< 10 min), so the rate was practically unaffected by the blank 
value from pure medium. 
The apparent linear lipolysis rate was determined for the different drug concentrations 
in medium-chain triglycerides and Figure 6-9 depicts the ANOVA results. We 
determined for Miglyol®812 alone a rate of 17.25 ± 1.45 µmol/min that was 
substantially higher than the means of the different compound groups. All drugs were 
obviously reducing the lipolysis rate of the oil. Comparing the different groups 
demonstrated a significant effect (p < 0.0001, confidence level of 95 %).) but this 
finding was mainly due to orlistat. This inhibitor of the pancreatic lipase was known 
to block the enzymatic reaction (Hadvàry et al., 1988; Hauptmann et al., 1992; Tiss et 
al., 2009). The other compounds had clearly overlapping confidence bands. Danazol, 
felodipine, fenofibrate, griseofulvin, and probucol belonged to a homogeneous group 
in the contrast analysis of the ANOVA so that their means of the apparent lipolysis 
rate could not be differentiated. 
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Figure 6-9: ANOVA means plot of drugs and their concentration effects on the apparent lipolysis rate 
No distinction was furthermore possible with respect to the different concentration 
groups. There was no overall effect with clearly overlapping confidence bands. We 
then inspected the individual compound results more thoroughly. A single-factor 
ANOVA was conducted for each individual compound to analyze the potential 
concentration effect on the apparent lipolysis rate, but again no statistical significance 
was observed. 
All the measurements were also performed in long-chain triglycerides. Data are not 
discussed, but the detailed results can be found in the appendix, section 9.2.2. 
6.4 Discussion 
It has been a theoretical concern that different drug concentrations in a formulation 
can first influence the lipolysis kinetics and may secondly lead to different drug 
solubilization in the evolving degradation phases. For example, different drug 
distributions in the digestion phases were shown by Kaukonen et al. for different 
compounds at a given concentration (Kaukonen et al., 2004). More recently, effects of 
drug distribution were analyzed for anethol trithione with varying lipid formulations 
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(Han et al., 2009). There is certainly a need to learn about concentration effects of 
different drugs and this work focused here entirely on the lipolysis kinetics. 
Our results did not demonstrate a significant drug concentration effect on the lipolysis 
kinetics. This lack of a concentration effect could be relevant for different dose 
strengths of a lipid-based drug delivery system. In contrast, there was a marked effect 
on lipolysis kinetics observed when comparing the drug-containing oils with the pure 
medium-chain triglycerides. Drug in oil lowered absolute NaOH consumption as well 
as inhibited the apparent rates of fatty acid generation if compared to oil alone. This 
effect could not be solely explained by the fact that dissolved drug replaced some 
parts of the digestible oil in a constant formulation amount. The concentrations in the 
formulations were generally below 5% (m/v) and even the highest solubilized drug 
amount of fenofibrate did similarly affect the apparent lipolysis rate to other drugs in 
much smaller concentrations in the oil. 
To gain a better mechanistic understanding of drug effects on lipolysis, the process 
must be considered as a heterogeneous enzyme reaction. Such reactions are complex 
and it was shown early that models of soluble enzymes have limited applicability in 
describing the kinetics of lipolysis (Panaiotov and Verger, 2000; Verger and 
Haas, 1976). Thus, lipolysis has become an emerging field of surface enzymology, 
which provides insights into the biopharmaceutical fate of lipid-based formulations 
(Aloulu et al., 2006). 
A simplified scheme of lipolysis is shown as a flow chart in Figure 6-10. The first 
step is here dispersion of oil or formulation and this is critical for generation of a high 
surface area. A study of Goddeeris et al. showed that higher stirring was leading to 
accelerated lipolysis (Goddeeris et al., 2007). The applied stirring energy is, however, 
only one parameter that can theoretically impact on oil dispersion. Thus, specific 
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interfacial energy as well as viscosity are other known parameters that can influence 
the dispersion step (Jahnke, 1998). Accordingly, there was an interest how viscosity 
or surface activity of drugs in oil were then affecting the lipolysis process. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-10: Simplified scheme of lipolysis 
Lipolysis of 
substrate 
Lipase adsorption 
on interface 
Transfer and 
structuring of 
lipolytic products 
Slight effect on 
surface 
generation 
Effect on 
"quality" of the 
interface   
Dispersion and 
surface 
generation 
 
Components of the formulation (drug, 
excipients) and of the medium (phospholipids 
and bile salts) can interact with different 
lipolytic process steps 
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The drugs increased viscosity overall, but the effects were rather subtle. Some 
contribution of viscosity to a general lipolysis inhibition cannot be ruled out but a 
viscosity impact on oil dispersion was not supported by our results. 
Some drugs clearly displayed surface activity. An amphiphilic character was already 
shown by the molecular modeling for danazol, felodipine, fenofibrate, griseofulvin, 
and orlistat. Subsequently, experimental surface activity was then mainly shown for 
felodipine and orlistat in medium-chain oil. These compounds were therefore likely to 
migrate to the oil/water interface and interaction with lipolysis possibly occurs. Such 
a direct interaction could influence the adsorption of lipase/colipase complex to the oil 
phase or it could perturb the enzymatic reaction itself. Some direct influence was for 
that reason expected for felodipine as well as a clear inhibition by orlistat. In the latter 
case inhibition was mostly based on direct interaction. In contrast, felodipine was not 
different from other compounds in lowering the apparent lipolysis rate. This result 
indicated that a predominant effect of the compound's surface activity was 
consequently not supported by our in vitro lipolysis results. 
It is well possible that indirect effects were mainly accounting for the general 
inhibition of lipolysis. Such an indirect effect can, for example, occur with the fate of 
the lipolytic products at the interface of the oil droplets. Figure 6-10 shows that 
lipolytic products are removed from the site of the enzymatic reaction. Thus, soluble 
short or medium-chain acids are mostly dissolved, while less soluble glycerides form 
liquid crystalline structures. Such structuring of lipolytic degradation products was 
investigated in the case of self-emulsifying systems and reviews highlighted the fate 
of enzymatic products in more detail (Fatouros et al., 2007; Fatouros and 
Muellertz, 2008; Porter et al., 2007). 
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The fate of lipolytic degradation products obviously plays a key role in the kinetics of 
the process. Products residing in the interface generally exert a surface pressure. 
Comparatively high surface pressure was shown to negatively affect lipolysis 
(Hall, 1992; Laurent et al., 1994). It can be generally assumed that any production of 
degradation products affects the "quality of the interface", which is a predominant 
factor for lipolysis kinetics (Verger and Haas, 1976). 
Noteworthy is that generation of surface-active degradation products can feedback on 
the dispersion process. This effect of a dynamic surface increases during lipolysis, 
which was experimentally shown by Kierkels et al., even though the importance of 
this mechanism to overall kinetics remains unclear (Kierkels et al., 1990). It might be 
less important than the "quality of the interface" with regard to the enzymatic 
reaction. 
It was important to realize that insoluble degradation products of the enzyme reaction 
can be dissolved by bile salts and phospholipids so that medium composition plays an 
important role for in vitro testing (Porter and Charman, 2001). Our results supported 
the view of a critical medium contribution. Thus, medium-chain oil was apparently 
slower digested in FaSSIF V2 than in another reported test medium (Sek et al., 2002). 
The kinetic difference was here mainly attributed to different media composition and 
pH of 7.5, which was higher than pH 6.5 in FaSSIF V2.  
The test medium may not only influence lipolysis by solubilization of the hydrolysis 
products, since components of the medium can also directly interact with the surface 
catalysis. Due to their surface activity, the phospholipids and bile salts are expected to 
adsorb to the oil/water interface so that a dynamic equilibrium with mixed micelles 
and vesicles in solution is attained (Embleton and Pouton, 1997). This equilibrium 
gives rise to the following hypothesis about indirect drug effects on lipolysis. 
EXPERIMENTAL SECTION 110 
 
 
All model compounds were poorly soluble so these drugs were prone to inclusion into 
the colloidal carriers, i.e. mixed micelles and vesicles (Galia et al., 1998; Ilardia-
Arana et al., 2006; Schwebel et al., 2010). The solubilized drug is expected to be 
partially dissolved in the oil as well as in the colloidal medium. However, the latter 
fraction of solubilized drug was depending on bile salts and phospholipids that were 
on the other hand in equilibrium with their adsorption on the oil/water interface. 
Moreover, bile salts and phospholipids were solubilizing lipolytic degradation 
products so that a competitive situation was given with drug solubilization in the 
medium. 
Given the complexity of the involved mechanisms, it becomes apparent that poorly 
soluble drugs can interact on several levels with the kinetics of the process (Figure 
6-10). Drugs can directly affect the quality of the interface or they can indirectly 
impact on lipolysis by an interaction with the biorelevant medium. A simple effect of 
drugs on oil viscosity or surface activity might have contributed to hinder lipolysis, 
but both factors appeared to play a minor role for in vitro lipolysis kinetics. 
6.5 Conclusions 
It was shown that a series of poorly soluble drugs exerted a strong effect on in vitro 
lipolysis kinetics using an updated biorelevant medium. Low drug concentrations 
were already affecting lipolysis, but no significant effect of drug loading was 
revealed. This was a promising result from a pharmaceutical viewpoint, since 
unchanged lipolysis kinetics for different drug loads means that there is possibly no 
unwanted variability arising different dose strengths. 
It was remarkable that the various drugs lowered lipolysis kinetics in a similar way. 
This was different from how the drugs affected viscosity or surface tension of the 
model oil. A direct compound effect on the oil could therefore not entirely explain the 
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observed effects in the digestion test. Probably indirect effects played a role, e.g. drug 
inclusion into colloids, so that the phospholipids and bile salts of the medium could 
not equally interact with the oil/water interface as with oil alone. Further testing can 
address such mechanistic aspects and the drug partitioning into the digestion phases 
should be studied. A continuous research in this area is required so that lipid-based 
formulations are in the future developed with an improved understanding of digestion 
processes. 
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7 IN VITRO DIGESTION KINETICS OF EXCIPIENTS 
FOR LIPID-BASED DRUG DELIVERY AND 
INTRODUCTION OF A RELATIVE LIPOLYSIS 
HALF LIFE  
7.1 Introduction 
Previous research on in vitro digestion provided viable information about the fate of 
triglyceride formulations and solubilized drugs in the intestinal tract (Christensen et 
al., 2004; Dahan and Hoffmann, 2007; Kaukonen et al., 2004; Porter et al., 2004). 
Lipolysis of pharmaceutical systems appears to be complex because the excipients are 
not only enzymatic substrates, but they can also act as inhibitors (MacGregor et 
al., 1997; Christiansen et al., 2010). Detection of excipient effects requires not only a 
sensitive in vitro test, but also the in vitro lipolysis should be robust and reliable to 
become a modern formulation development tool. 
Research is needed to make different lipolysis tests better comparable. It is favorable 
to have kinetic test data that are relative to a standard and therefore bear the potential 
to be independent of the given experimental conditions. Such a relative kinetic 
parameter would have to be obtained from a kinetic theory of in vitro lipolysis. In line 
with these considerations, this work aimed at first studying the lipolysis of nine 
pharmaceutical excipients and then analyzing the data using a mathematical model. 
The final goal was to define a relative kinetic parameter by normalizing an obtained 
lipolysis half life with the corresponding value from the reference oil Miglyol®812. 
 
 
 
113 EXPERIMENTAL SECTION 
 
 
7.1.1 Theory 
Kinetics of lipolysis is complex because it's a heterogeneous catalysis at the oil/water 
interface. Excellent reviews were written by Aloulou et al. (2006), Panaiotov et 
al. (1997), as well as Verger and Haas (1976). 
 
An attempt was made to adopt the Michaelis-Menten kinetics as an approximation of 
lipolysis rate (Laidler and Bunting, 1973): 
  
v = vm '
S[ ]
Km '+ S[ ]                   (7.1) 
The maximal rate vm' and the Michaelis-Menten constant Km' are here understood as 
apparent parameters, since the original model was described for a homogeneous and 
not for a heterogeneous catalysis. It is therefore unclear, how well the theory can be 
adapted to lipolysis that takes place at the oil/water interface. 
 
There are alternative kinetic models, which are based on simplifications. Kosugi and 
Suzuki (1983) proposed a one-substrate, first-order kinetics to describe the lipolysis 
process under the assumption that the committed step of the entire reaction is the ester 
hydrolysis. Therefore, one substrate reacts with a water molecule at the oil/water 
interface to yield product molecules named P and Q. The product concentration [P] or 
[Q] can be expressed in terms of the concentration of all ester bonds at the start of 
lipolysis [S]0 minus its value at a given time point [S]: 
  
[P] = Q[ ]= S[ ]0 − S[ ]                 (7.2) 
The progress of the lipolysis reaction can be described by the parameter X, which was 
called lipolysis degree, and represents the ratio between the product and the original 
substrate concentration: 
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X =
S[ ]0 − S[ ]
S[ ]0
                 (7.3) 
Thus, the rate is expressed as a function of the product concentrations using the 
hydrolysis reaction constant k1, while assuming reversibility by introducing the 
constant k
-1:  
  
v = −
d S[ ]
dt
= k1 S[ ]− k−1 P[ ] Q[ ]                (7.4) 
  
dX
dt
= k1(1− X) − k−1 S[ ]0X2                   (7.5) 
This model was proposed by Knezevic et al. for a lipolysis reaction in general 
(Knezevic et al., 1998). We consider the underlying assumptions as a first 
approximation of the kinetics from in vitro lipolysis. However, the late phase of 
lipolysis probably involves factors that are not considered in the present model. More 
advanced models would have to include the role of the interface and how it changes in 
the progress of the reaction. Accumulation of products on the oil surface forms a 
viscous layer that is expected to influence lipolysis (Embleton and Pouton, 1997). 
Furthermore not all ester bonds might be kinetically the same so that consecutive 
reactions can occur, leaving the less accessible ester bonds for the late stage of 
lipolysis. Different mechanisms therefore lead to a decreasing hydrolysis rate and the 
present model just holds for a simple approach to model an equilibrium that is reached 
asymptotically. 
 
At the equilibrium, equation 7.5 becomes zero and X reaches the plateau value XE. 
  
k1 1− X( )− k−1 S[ ]0X2 = 0                 (7.6) 
This equilibrium condition can be used for substituting k
-1 and to obtain equation 7.7: 
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dX
dt
=
k1 XE −1( )X2 − XE2X + XE2[ ]
XE
2                 (7.7) 
This differential equation can be integrated and the mathematical derivation of the 
equation below was published by Knezevic et al. (1998): 
  
X =
1− (3 − XE)− t / h( )XE
1+ (1− XE )(3 − XE)− t / h
                  (7.8) 
where h is termed "lipolysis half life" and holds for the time needed to reduce the 
initial substrate concentration by a factor of two. 
In vitro lipolysis testing is a special form of lipase-catalyzed hydrolysis given the 
comparatively small amount of formulation and the presence of bile salts as well as 
Ca2+-ions. Under these conditions, complete lipolysis frequently occurs. Accordingly, 
in this situation we assumed that the lipolysis degree XE gets close to unity, which 
greatly simplifies the result: 
  
X =1− 2−t/h                     (7.9) 
A linear plot can be obtained by rearranging the equation 7.9 to: 
  
ln(1− X) = − ln(2)
h
t                (7.10) 
The lipolysis half life h can be inferred from the slope of the ln(1-X) plot . Finally, it 
makes sense to have relative values of this kinetic measure. Normalization by the 
value of a standard sample, e.g. Miglyol®812, was used to define the "relative 
lipolysis half life": 
  
h rel =
h(sample)
h(reference)                (7.11) 
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7.2 Materials and Methods 
7.2.1 Materials 
Calcium chloride, maleic acid, porcine pancreatin, sodium chloride, sodium 
hydroxide, and 0.2 N sodium hydroxide were purchased from Sigma-Aldrich GmbH, 
Switzerland. Imwitor®742, Miglyol®812, and PS80 were obtained from Hänseler AG, 
Switzerland. Imwitor®742 is a blend of mono-, di-, and triglycerides, mostly caprylic 
(C8:0) and capric acid (C10:0). The fraction of monoglycerides was 44% to 55%. 
Miglyol®812 is a medium-chain oil consisting of 50% to 65% caprylic acid (C8:0) and 
30% to 45% of capric acid (C10:0). A maximal amount of 2% was specified for caproic 
acid (C6:0) as well as for lauric acid (C12:0). Finally, the content of myristic acid (C14:0) 
was maximally 1%. Capryol™90, Lauroglycol™90, Labrafil®M-2125 CS, and 
Gelucire®44/14 were purchased from Gattefossé GmbH, France. Capryol™90 
(propylene glycol monocaprylate) consisted of 99.6% caprylic acid (C8:0) and 
Lauroglycol™90 (propylene glycol monolaurate) contained 99.1% lauric acid (C12:0) 
and 0.1% capric acid (C10:0). Labrafil®M-2125 CS is a well-defined mixture of mono-, 
di-, and triglycerides as well as mono- and di-fatty acid esters of polyethylene glycol. 
The fatty acid moieties were 52.1% linoleic acid (C18:2), 32.2% oleic acid (C18:1), and 
10.8% palmitic acid (C16:0). The amount for stearic acid (C18:0) was 2%, for linolenic 
acid (C18:3) 1%, for arachidic acid (C20:0) 0.5%, and 0.4% for eicosenoic acid (C20:1). 
Gelucire®44/14 is, similar to Labrafil®M-2125 CS, a well-defined mixture of mono-, 
di-, and triglycerides as well as mono- and di-fatty acid esters of polyethylene glycol. 
The amount of lauric acid (C12:0) was 44.7%, 18.2% for myristic acid (C14:0), 9.6% for 
palmitic acid (C16:0), and 11.7% for stearic acid (C18:0). The content of caprylic acid 
(C8:0) was 7.29% and for capric acid (C10:0) it was 5.47%. Capmul®MCM was 
obtained from Abitec Corp., United States. This mixture of medium-chain mono- and 
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diglycerides contained 82.6% caprylic acid (C8:0) and 17.4% capric acid (C10:0). 
Cremophor®RH 40 (Macrogol-Glycerolhydroxystearat Ph.Eur.) was obtained from 
BASF AG, Switzerland. 
Sodium taurocholate was purchased from Prodotti Chimici e Alimentari S.p.A., Italy, 
and phosophatidylcholine was obtained from Lipoid GmbH, Germany. 
7.2.2 Methods 
7.2.2.1 Preparation of biorelevant medium and lipase solution 
The enzymatic tests were conducted in FaSSIF V2 (Jantratid et al., 2008). This 
medium was used as reaction medium as well as medium for the suspension of 
porcine pancreatin (0.174 mg pancreatin/ml medium). Following stirring of the 
mixture at room temperature (15 min, 25 ± 0.5°C), the dispersion was centrifuged 
using an Eppendorf 5415C Centrifuge (Vaudaux-Eppendorf AG, Switzerland) for 15 
min at 14000 rpm. The clear supernatant was collected and pH 6.5 was adjusted. The 
resulting solution exhibited an enzyme activity of 10000 TBU/ml. This solution 
(pancreatic extract) was freshly prepared each day. 
7.2.2.2 In vitro lipolysis test 
Excipient (500 mg) was dispersed in 36 ml medium at 37°C in a double walled glass 
vessel. The solution was then equilibrated for 15 min to then start the lipolysis by 
adding 4 ml pancreatin extract (1000 TBU/ml final concentration) and 5 mM calcium 
chloride dihydrate. During lipolysis, the pH was kept constant using a Titrando 842 
(Metrohm Schweiz AG, Switzerland) that titrated the liberated free fatty acids with 
0.2 N NaOH solution. 
7.2.2.3 Statistical Design and analysis of data 
All measurements were conducted in triplicates and results were expressed as mean 
values ± standard deviations. For the regression analysis, the program Statgraphics 
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Centurion XV ed. Professional from StatPoint Technologies, Inc., United States, was 
used. 
7.3 Results 
7.3.1.1 NaOH consumption and lipolysis degree 
The titrated NaOH volume to keep the pH 6.5 constant was measured. Consumed 
equivalents of 0.2 N NaOH corresponded to the liberated free fatty acids during the 
reaction.  
 
Figure 7-1: Lipolysis profiles of excipients having comparatively high NaOH consumption 
Figure 7-1 and Figure 7-2 show lipolysis results of different excipients during the 
first hour. Pronounced differences were observed in terms of the kinetic profiles. The 
curves levelled off as a function of time at different values. Fig. 1 depicts a first group 
of excipients having comparatively high NaOH consumption. This group included 
mono-, di-, and triglycerides, i.e. Miglyol®812, Capmul®MCM, and Imwitor®742. 
Further highly digestible excipients in this group were Capryol™90 as well as 
Gelucire®44/14. All of these excipients obviously released comparatively high 
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amounts of free fatty acids even though differences were observed with respect to 
their individual kinetics. Thus, Capmul®MCM and Imwitor®742 had the fastest and 
the highest NaOH consumption, followed by Capryol™90. Compared with these 
excipients, the kinetics of medium-chain triglyceride Miglyol®812 was rather slow 
and the values barely levelled off within the first hour of lipolysis. This was different 
from Gelucire®44/14 for which the highest NaOH consumption was reached rather 
quickly. A similar trend was further observed with some of the excipients of the 
second group (Figure 7-2). 
 
Figure 7-2: Lipolysis profiles of excipients having moderate NaOH consumption 
Figure 7-2 displays a group of excipients with moderate NaOH consumption. 
Interestingly, the excipients curves of Cremophor®RH 40, Labrafil®M-2125 CS, and 
PS80 levelled off quickly. However, the NaOH consumption was low with a value 
below 1 ml. Lauroglycol™90 ranked among the second group. It is a propylene 
glycol monolaurate differing from the PEGylated excipients with respect to lipolysis 
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results. In fact, steadily increasing values were observed while no plateau was reached 
within the first minutes of lipolysis. 
 
Differences in absolute NaOH consumption did not directly reflect the lipolysis 
degree, i.e. how many of the available ester bonds were hydrolyzed. The lipolysis 
degree can only be calculated referring on the overall number of the available ester 
bonds. To define the estimated hydrolysis maximum (EHM), we selected the mean 
saponification value that was inferred from the excipient specifications. Based on this 
value, a theoretical maximum titration volume was estimated. 
Excipient EHM (ml) 
NaOH 
consumption 
 after 3 h (ml) 
Lipolysis degree 
after 3 h (%) 
Miglyol®812 14.95 10.86 ± 0.04 72.6 
Capryol™90 12.5 9.02 ± 0.15 72.2 
Capmul®MCM 12.05 11.93 ± 0.23 99.0 
Imwitor®742 11.8 11.04 ± 0.50 93.6 
Lauroglycol™90 9.6 2.40 ± 0.13 25.0 
Labrafil®M-2125 CS 7.15 1.42 ± 0.14 19.9 
Gelucire®44/14 3.6 3.60 ± 0.14 100.0 
Cremophor®RH40 2.45 0.85 ± 0.02 34.7 
Polysorbate 80 2.25 1.20 ± 0.11 53.3 
Table 7-1: Estimated hydrolysis maximum (EHM) and the experimental lipolysis degree after 3 h for 
each excipient 
Table 7-1 shows the EHM in ml of 0.2 N NaOH solution for all the tested 
excipients. The EHM was compared to the NaOH consumption after 3 h. This point in 
time was selected from the physiological consideration that it roughly estimates the 
upper limit of the residence time that is still reasonable for lipolysis in the small 
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intestinal tract. Some values after 3 h were in the same range as the EHM and other 
excipients reached only a fraction thereof. We used the EHM as 100% value to 
calculate the lipolysis degree that was interesting to consider after the rather long time 
of 3 h. Excipients that reached more than 70% of total lipolysis were considered as 
highly digestible. Accordingly, the excipients Miglyol®812, Capmul®MCM, 
Capryol™90, Imwitor®742, and Gelucire®44/14 displayed almost complete lipolysis 
of hydrolyzable ester bonds. 
7.3.1.2 Kinetic data as ln(1-X) plot and definition of a relative lipolysis half life 
According to the model, linearity of the ln(1-X) plot versus time is expected for 
excipients that are completely digested. Therefore only excipients with a lipolysis 
degree of > 70% at 3 h were selected for this analysis. Moreover, the evaluation was 
limited to the initial phase of lipolysis because of the simple model assumptions 
seemed to be less suitable for the complex equilibrium phase of lipolysis. 
Figure 7-3: ln(1-X) plot for Miglyol®812 
ln
(1-
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Miglyol 812
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Figure 7-4: ln(1-X) plot for Capryol™90 
Figure 7-3 depicts the plot for Miglyol®812 and Figure 7-4 shows the plot 
Capryol™90. High R2 values were observed despite the simplicity of the model. 
Table II lists the slopes of the regression lines as well as the standard errors with 95% 
confidence intervals. Based on the slope, the lipolysis half life was calculated (Table 
7-2).  
Excipient Slope  (*10-4 s-1) 
SE 
(*10-4 s-1) 
95% confidence 
interval (*10-4 s-1) 
R2 
(%) 
Lipolysis 
half life 
(s) 
Miglyol®812 -2.07 0.04 (-2.14) - (-1.99) 95.2 3349 
Capryol™90 -6.61 0.16 (-6.93) - (-6.29) 91.6 1049 
Capmul®MCM -9.70 0.16 (-10.0) - (-9.38) 96.4 715 
Imwitor®742 -8.62 0.23 (-9.10) - (-8.14) 89.5 804 
Gelucire®44/14a) -8.75 0.34 (-9.45) - (-8.05) 96.9 792 
a)
 An intercept was fitted with -0.268 s-1 and an SE of 0.026 s-1, SE: standard error 
Table 7-2: Statistical evaluation of the linear regression model 
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Figure 7-5: ln(1-X) plot for Capmul®MCM 
 
 
 
 
 
 
 
 
 
 
 
Figure 7-6: ln(1-X) plot for Imwitor®742 
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As shown in Figure 7-5 and Figure 7-6, a suitable model fit was further 
demonstrated for Capmul®MCM and Imwitor®742. It was interesting to note that 
Gelucire®44/14 needed an assumed intercept for the linear regression. This PEGylated 
excipient obviously required this intercept as an experimental correction term. It was 
possibly due to an initial NaOH volume that was consumed apart from the lipolysis 
reaction. Figure 7-7 displays the ln(1-X) values of Gelucire®44/14 as a function of 
time. A good first approximation of the initial lipolysis kinetics was attained, which 
was also reflected by a high correlation coefficient (Table 7-2). 
 
 
 
 
 
 
 
 
 
 
 
Figure 7-7: ln(1-X) plot for Gelucire®44/14 
To obtain a relative kinetic parameter, a reference excipient had to be selected. We 
used Miglyol®812 as reference for the calculation of the relative lipolysis half life. As 
shown in Table 7-3, the values ranged from 0.21 in case of Capmul®MCM to 0.31 
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for Capryol™90. Lipolysis of pure reference oil was obviously substantially slower 
than that of the other excipients. 
Excipient Lipolysis half life (s) 
Miglyol®812 (reference) 1 
Capryol™90 0.31 
Capmul®MCM 0.21 
Imwitor®742 0.24 
Gelucire®44/14 0.24 
Table 7-3: Lipolysis half life, using Miglyol®812 as reference 
7.4 Discussion 
The tested excipients ranged from mixtures of mono-, di-, and triglycerides as well as 
non-ionic PEGylated surfactants. It was interesting to note that excipients with 
medium-chain-length esters generally displayed high fatty acid titration levels and 
nearly complete lipolysis. This was true for Miglyol®812, Capryol™90, 
Capmul®MCM as well as for Imwitor®742. We also found a difference in the 
digestion kinetics of another chemical group, namely the propylene glycol esters. The 
monocaprylate Capryol™90 was among the highly digested excipients, whereas the 
monolaurate ester Lauroglycol™90 showed incomplete lipolysis. Not all lauryl-acid 
containing excipients were incompletely hydrolyzed as can be seen from the example 
of Gelucire®44/14. Longer chain derivatives like the oleyl polyglycerides of 
Labrafil®M-2125 CS, or the PEGylated sorbitant monooleate PS80 further 
demonstrated that only a low lipolysis degree could be reached. A comparatively low 
digestion plateau was moreover reached with Cremophor®RH 40, which is a 
PEGylated hydrogenated castor oil. 
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Chain length was certainly not the only factor that influenced the lipolysis kinetics. 
Miglyol®812 was slower hydrolyzed than the other completely digested excipients. 
There was a clear distinction between the pure triglyceride and the mixtures of mono-, 
di-, and triglycerides of medium-chain length, i.e. Capmul®MCM and Imwitor®742. 
These partial glycerides were expected to have a lower specific energy at the 
water/excipient interface and higher initial surface generation could explain the 
increased lipolysis rates. However, this aspect of dispersibility and surface generation 
must be viewed differently if PEGylated surfactants are considered. 
Gelucire®44/14 is a PEGylated surfactant that has been widely used in self-
emulsifying drug delivery systems and its susceptibility to digestion was reported 
before (Fernandez et al., 2009). It was still remarkable that the excipient revealed a 
complete lipolysis. Bulky PEG chains can hinder sterically the lipolysis process. 
However, the ester bonds in Gelucire®44/14 were obviously well accessible to the 
enzyme. This was in contrast to the maximal lipolysis degree of Labrafil®M-2125 CS, 
Cremophor®RH 40, and PS80. Therefore, the effect may not solely depend on the 
fatty acid chain length. It was earlier reported that Cremophor®RH 40, and PS80 were 
both inhibiting pancreatic lipase if triglycerides were digested in vitro (Christiansen et 
al., 2010). This recent finding supported the pioneering work of Gargouri et al. who 
studied the surfactant effects on inhibition of lipase (Gargouri et al., 1983). 
Surfactants interfere with the lipolysis of triglycerides and they can be digested 
themselves. Such digestion of functional excipients typically affects the drug 
solubilization behaviour. Cuiné et al. showed that formulations with high quantities of 
digestible surfactant prevented drug precipitation less effectively (Cuiné et al., 2007). 
These effects must be known in formulation development to avoid drug precipitation 
in the gastro-intestinal tract due to the loss of surfactants in the course of digestion. 
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Our study focused on the lipolysis kinetics of single excipients, which might be a start 
for future research. For this purpose we suggested a new theoretical concept for the 
analysis of the kinetic data. We have to keep in mind that many simplifications were 
made. The basic kinetic model only focused on ester hydrolysis as the committed 
step. All ester bonds were treated equally even though an experimental substrate can 
have different ester types. Thus, consecutive reactions can be a reason for changing 
kinetics as a function of time. It is mainly the phase close to the equilibrium that 
seems to be rather complex. It was mentioned earlier that the effect of accumulated 
degradation products on the droplet surface can lead to viscous structures. Biophysical 
analysis of these mesophases has become a research topic in its own right (Fatouros 
and Muellertz, 2008). The effect of such structures on the lipolysis kinetics is not 
clear on a mechanistic level and such effects were not considered in the proposed 
model. 
We studied the initial lipolysis phase of those excipients that were extensively 
hydrolyzed using a ln(1-X) versus time plot. The theoretical linearity was 
experimentally verified with these additives. It should not be forgotten that neither the 
excipients nor the pancreatic extract are pure substances, but rather complex mixtures. 
In light of the simplicity of the underlying theory, it was therefore remarkable that the 
group of extensively digested excipients indeed exhibited a fair linearity in the ln(1-
X) plot. However, there was a trend in the residuals detected, which underlined the 
model to hold for a first approximation only. 
The theoretical concept differentiates between the equilibrium lipolysis degree XE and 
complete lipolysis, where this value reaches unity. This is an important differentiation 
and care is needed when comparing with another lipolysis extent that is defined 
differently by simply taking the given equilibrium value as 100%. Our results clearly 
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demonstrated that some excipients had residual ester bonds that were not cleaved 
during lipolysis. In this respect, the estimated hydrolysis maximum was a helpful 
concept. It indicated a maximal ester concentration because the used saponification 
number was determined under harsher hydrolysis conditions as compared to the in 
vitro lipolysis test. 
To consider the maximal concentration of ester bonds, Ali et al. tried a different 
theoretical approach (Ali et al., 2007). It was assumed that during lipolysis one mole 
of triglyceride is hydrolyzed to one mole of 2-monoglycerides and two moles of free 
fatty acids. The equivalents of maximal titration solution can then be calculated by 
considering the main specified oil components. However, care is needed since the 2-
monoglycerides can undergo a non-enzymatic isomerisation to 1-monoglycerides that 
can be digested by the pancreatic lipase to glycerol and a fatty acid (Embleton and 
Pouton, 1997). Thus, values of lipolysis degree or lipolysis extent should be carefully 
compared in the literature by considering the given definitions. 
Comparison of lipolysis data from different origins was a main reason to introduce the 
relative lipolysis half life. By calculating relative values to standard oil, the 
dependence on the given experimental conditions is lower than if absolute kinetic 
values are compared. We used the medium-chain triglycerides Miglyol®812 as 
reference. Even though the oil was arbitrarily selected, the choice was reasonable with 
our data, since the other excipients were all hydrolyzed much faster so that values 
below one were obtained. However, based on our knowledge of comparatively slower 
hydrolysis of long-chain triglycerides, we expect that other oils of longer chain length 
reach relative lipolysis half lives of greater than one. We certainly need more data and 
further digestion experiments with other excipients as well as drug delivery systems. 
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This will ultimately show the usefulness of the relative lipolysis half life in comparing 
kinetic data from different in vitro lipolysis tests. 
7.5 Conclusions 
A series of excipients were digested in vitro and a kinetic theory was adapted to 
describe the obtained lipolysis data. The excipients were classified into partially and 
entirely digesting additives. In line with the theory, the latter group displayed linear 
plots of ln(1-X) versus time and the slope was used to estimate a lipolysis half life. A 
relative lipolysis half life was subsequently defined to normalize the kinetic measure 
based on the given experimental in vitro conditions. Progress was made in better 
characterising the in vitro digestion of pharmaceutical excipients. The ln(1-X) versus 
time plot can be used as a promising tool for the analysis of future in vitro lipolysis 
results. A proper assessment of the lipolysis kinetics is an important step because it 
defines the formulation changes over time. If the formulation is changing in the 
course of lipolysis, the main concern is whether a poorly water-soluble drug can still 
be kept in solution. Drug precipitation can greatly limit the oral absorption of such 
drugs and future research should focus on the link between kinetic changes of 
lipolysis and the kinetics of potential drug precipitation. Only a proper understanding 
of the in vitro performance can form a solid basis for good correlations with in vivo 
data of lipid drug delivery systems. 
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8 OUTLOOK 
In this study, we gained new insight into dissolution and lipolysis processes based on 
in vitro tests using biorelevant media. The factors influencing the processes under 
physiological conditions are versatile thus rendering detailed insight rather 
challenging. As a first step, lipolysis tests should be standardized, as was done with 
dissolution tests. At present, the results of all existing lipolysis tests cannot be 
compared due to the highly variable experimental procedures. Standardization of in 
vitro lipolysis tests would simplify the cross-comparison of data, and therefore 
accelerate the improvement of a systematic understanding of lipolysis.  
 
In future work, experimental settings might be expanded to include gastric processes 
and absorption steps. Absorption tests using cells already exist, but there is still 
potential for improvement. Since some cells, e.g. Caco-2 cells, are sensitive to bile 
salts and surfactants, the usefulness of these cells has yet to be demonstrated. 
However, for a simulation close to reality and enhancing the predictability of in vivo 
dissolution of drugs, the inclusion of additional steps is necessary.  
 
We introduced analytical tools such as Raman spectroscopy, particle analyzer, and 
FBRM. These tools seemed to be able to monitor the precipitation processes in spite 
of the turbidity of some media. It would be interesting to introduce other tools and to 
check the ability of process monitoring in biorelevant media.   
 
Our proposed mathematical models are useful for the description of precipitation and 
lipolysis processes. The model for precipitation was only adopted for a weakly basic
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model drug. The usefulness of this model for acidic and neutral drugs has yet to be 
proven. It would be interesting to see if the model is also able to describe the process 
of precipitation of other classes of drugs. The usefulness of the model for a drug 
dissolved in lipid-based formulations remains an open question.  
The mathematical model for lipolysis kinetics was applied for different excipients, 
indicating that the crucial step during lipolysis is not only ester hydrolysis. Additional 
steps have to be included to improve the validity of the model. Moreover, the model 
can be adapted to formulations including poorly water-soluble drugs. 
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9 APPENDIX 
9.1 Appendix of chapter 4  
9.1.1 Calculation of used amounts of media and API 
The used amount of media was based on the assumption, that the patient takes the 
drug together with 200 ml of water. The volume of the fasted stomach medium was 
100 ml. One-third of the fenofibrate was either precipitated or absorbed in the 
stomach. Therefore only two-third of API in 100 ml stomach medium/water moved 
into 200 ml intestinal medium. The amounts were scaled down by a factor 6 to a total 
volume of 50 ml.  
Drug concentrations were calculated based on the product Lipanthyl® which contains 
100 mg to 267 mg fenofibrate. 
133 APPENDIX 
 
 
9.1.2 FBRM counts/s at the start of the experiment, before 
nucleation started 
Figure 9-1: Biorelevant media mixture, 37°C: FBRM counts/s at the beginning of the experiment as a 
function of the biorelevant media batch, before nucleation started 
The FBRM counts/s just after the addition of FaSSIF V2 in the range of 1 µm to 
20 µm were recorded before nucleation started. The FBRM counts/s were ≠ 0 and the 
values showed variations, neither related to the amount of PS80 in the formulation nor 
to the media batches (Figure 9-1). The latter had no influence in our experiments, 
because the production of the media was always based on exactly the same procedure. 
The main reason for the particle number variation was precipitation of fenofibrate in 
FaSSGF. Not all the formulations were able to keep the drug in a solubilized state 
during the simulated stomach passage. Previously, equilibrium solubilities in the 
stomach were measured.  A two fold solubility of fenofibrate in FaSSGF resulted 
compared to the solubility in FaSSIF V2. Therefore it was reasonable, that 
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precipitation occurred in the simulated stomach. As a consequence, initial precipitates 
in FaSSGF were moved to the simulated intestine, which resulted in a variable 
number of the FBRM counts/s before nuleation started.  
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9.2 Additional results of chapter 6 using medium- and long- 
chain triglycerides 
9.2.1 Additional data using medium-chain triglycerides 
 
Surface tension ± std. (mN/m) of different drug 
concentrations in MCT 
(value of pure oil: 36.13 ± 0.15) 
 Low Intermediate High 
Danazol 35.7 ± 0.2 35.4 ± 0.1 35.6 ± 0.1 
Felodipine 34.5 ± 0.1 34.6 ± 0.1 35.1 ± 0.2 
Fenofibrate 35.8 ± 0.1 36.4 ± 0.1 36.9 ± 0.2 
Griseofulvin 35.9 ± 0.1 35.9 ± 0.0 38.6 ± 0.1 
Probucol 36.1 ± 0.1 36.0 ± 0.1 36.1 ± 0.1 
Orlistat 35.1 ± 0.1 34.8 ± 0.1 34.7 ± 0.1 
*Surface age of 25 ms 
Table 9-1: Surface tension of different drug concentrations in MCT, surface age 25 ms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX 136 
 
 
 
 
 
Surface tension ± std. (mN/m) of different drug 
concentrations in MCT 
(value of pure oil: 29.57 ± 0.06) 
 Low Intermediate High 
Danazol 29.5 ± 0.0 29.5 ± 0.0 29.5 ± 0.1 
Felodipine 27.9 ± 0.1 29.8 ± 0.3 29.3 ± 0.2 
Fenofibrate 29.6 ± 0.1 29.8 ± 0.2 30.1 ± 0.1 
Griseofulvin 29.6 ± 0.2 29.5 ± 0.1 32.8 ± 0.3 
Probucol 32.8 ± 0.2 29.7 ± 0.2 29.5 ± 0.1 
Orlistat 28.0 ± 0.2 27.9 ± 0.1 27.8 ± 0.0 
*Surface age of 250 ms 
Table 9-2: Surface tension of different drug concentrations in MCT, surface age 250 ms 
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Density ± std. (g/cm3) of MCT including different drug 
concentrations  
(value of pure oil: 0.938 ± 0) 
 Low Intermediate High 
Danazol 0.938 ± 0 0.938 ± 0 0.938 ± 0 
Felodipine 0.938 ± 0 0.938 ± 0 0.938 ± 0 
Fenofibrate 0.939 ± 0 0.943 ± 0 0.947 ± 0 
Griseofulvin 0.938 ± 0 0.938 ± 0 0.938 ± 0 
Probucol 0.938 ± 0 0.938 ± 0 0.938 ± 0 
Orlistat 0.938 ± 0 0.938 ± 0 0.938 ± 0 
Table 9-3: Density of MCT including different drug concentrations  
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9.2.2 Additional data using long-chain triglycerides 
 Drug concentrations in LCT (mg/ml) 
 Low Intermediate High 
Danazol 0.35 0.57 1.31 
Felodipine 0.43 1.68 3.33 
Fenofibrate 2.50 25.30 50.00 
Griseofulvin 0.27 0.57 0.88 
Itraconazole 0.17 0.41 0.62 
Probucol 1.8 10.32 25.02 
Orlistat 5.00 10.00 20.00 
Table 9-4: Drug concentration levels in LCT 
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Kinematic viscosity ± std. (mm2/s) of different drug 
concentrations in LCT 
(value of pure oil: 72.9 ± 0.1) 
 Low Intermediate High 
Danazol 73.7 ± 0.5 73.4 ± 0.3 71.4 ± 0.4 
Felodipine 73.3 ± 0.9 72.5 ± 0.9 72.3 ± 1.3 
Fenofibrate 70.6 ± 0.7 74.9 ± 0.2 80.1 ± 1.3 
Griseofulvin 72.4 ± 0.8 73.0 ± 1.6 74.1 ± 0.6 
Itraconazole 72.9 ± 0.4  72.7 ± 0.3 72.7 ± 0.6 
Probucol 73.0 ± 1.8 74.6 ± 0.1 79.8 ± 0.7 
Orlistat 73.1 ± 1.9 73.0 ± 1.6 78.2 ± 0.5 
Table 9-5: Kinematic viscosity of different drug concentrations in LCT 
 
 
Figure 9-2: ANOVA means plot of drugs and their concentration effects on kinematic viscosity in 
LCT (means and 95% LSD intervals) 
 
 
APPENDIX 140 
 
 
 
 
Surface tension ± std. (mN/m) of different drug 
concentrations in LCT 
(value of pure oil: 50.40 ± 0.36) 
 Low Intermediate High 
Danazol 51.0 ± 0.1 51.0 ± 0.5 50.8 ± 0.3 
Felodipine 49.5 ± 0.1 49.6 ± 0.3 50.5 ± 0.3 
Fenofibrate 52.4 ± 0.2 53.0 ± 1.3 56.3 ± 1.2 
Griseofulvin 51.4 ± 0.3 51.9 ± 0.1 51.6 ± 0.1 
Itraconazole 51.3 ± 0.3 51.0 ± 0.4 51.2 ± 0.4 
Probucol 51.9 ± 0.6 51.3 ± 0.1 51.8 ± 0.2 
Orlistat 50.8 ± 0.1 50.5 ± 0.1 51.1 ± 0.3 
*Surface age of 25 ms 
Table 9-6: Surface tension of different drug concentrations in LCT, surface age 25 ms 
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Surface tension ± std. (mN/m) of different drug 
concentrations in LCT 
(value of pure oil: 34.97 ± 0.12) 
 Low Intermediate High 
Danazol 35.6 ± 0.1 36.1 ± 0.5 37.0 ± 0.2 
Felodipine 33.0 ± 0.0 31.1 ± 0.0 35.1 ± 0.2 
Fenofibrate 35.4 ± 0.1 35.9 ± 0.2 36.3 ± 1.0 
Griseofulvin 36.8 ± 0.2 35.3 ± 0.1 36.3 ± 0.1 
Itraconazole 35.6 ± 0.1 35.2 ± 0.1 35.3 ± 0.0 
Probucol 35.8 ± 0.0 35.7 ± 0.0 36.3 ± 0.2 
Orlistat 33.3 ± 0.1 35.9 ± 0.0 33.5 ± 0.3 
*Surface age of 250 ms 
Table 9-7: Surface tension of different drug concentrations in LCT, surface age 250 ms 
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Surface tension ± std. (mN/m) of different drug 
concentrations in LCT 
(value of pure oil: 33.2 ± 0.4) 
 Low Intermediate High 
Danazol 32.9 ± 0.1 33.9 ± 0.2 34.5 ± 0.2 
Felodipine 30.2 ± 0.2 30.3 ± 0 32.4 ± 0.3 
Fenofibrate 32.3 ± 0.1 33.6 ± 0.2 35.2 ± 0.3 
Griseofulvin 34.1 ± 0.2 34.3 ± 0.2 33.6 ± 0.2 
Itraconazole 34.3 ± 0.1 33.0 ± 0.7 32.4 ± 0.1 
Probucol 32.3 ± 0.1 33.8 ± 0.3 33.3 ± 0.2 
Orlistat 30.2 ± 0.1 30.2 ± 0.1 30.2 ± 0.1 
*Surface age of 2500 ms 
Table 9-8: Surface tension of different drug concentrations in LCT, surface age 2500 ms 
 
 
Figure 9-3: ANOVA means plot of drugs and their concentration effects on surface tension in LCT 
(means and 95% LSD intervals) 
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Density ± std. (g/cm3) of LCT including different drug 
concentrations  
(value of pure oil: 0.910 ± 0) 
 Low Intermediate High 
Danazol 0.910 ± 0 0.910 ± 0 0.910 ± 0 
Felodipine 0.909 ± 0 0.910 ± 0 0.910 ± 0 
Fenofibrate 0.910 ± 0 0.915 ± 0 0.921 ± 0 
Griseofulvin 0.910 ± 0 0.910 ± 0 0.910 ± 0 
Itraconazole 0.910 ± 0 0.910 ± 0 0.910 ± 0 
Probucol 0.910 ± 0 0.911 ± 0 0.913 ± 0 
Orlistat 0.910 ± 0 0.910 ± 0 0.911 ± 0 
Table 9-9: Density of LCT including different drug concentrations 
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Figure 9-4: NaOH consumption in ml throughout lipolysis of 0.5 ml peanut oil and 0.5 ml peanut oil 
including three concentrations of danazol 
 
 
Figure 9-5: NaOH consumption in ml throughout lipolysis of 0.5 ml peanut oil and 0.5 ml peanut oil 
including three concentrations of felodipine 
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Figure 9-6: NaOH consumption in ml throughout lipolysis of 0.5 ml peanut oil and 0.5 ml peanut oil 
including three concentrations of fenofibrate 
 
 
Figure 9-7: NaOH consumption in ml throughout lipolysis of 0.5 ml peanut oil and 0.5 ml peanut oil 
including three concentrations of griseofulvin 
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Figure 9-8: NaOH consumption in ml throughout lipolysis of 0.5 ml peanut oil and 0.5 ml peanut oil 
including three concentrations of itraconazole 
 
 
Figure 9-9: NaOH consumption in ml throughout lipolysis of 0.5 ml peanut oil and 0.5 ml peanut oil 
including three concentrations of probucol  
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Figure 9-10: NaOH consumption in ml throughout lipolysis of 0.5 ml peanut oil and 0.5 ml peanut oil 
including three concentrations of orlistat 
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